

FILED

2016 JUN 13 PM 1:27

U.S. DISTRICT COURT
CENTRAL DIST. OF CALIF.
LOS ANGELES

David L. Scher, Esq.
dscher@employmentlawgroup.com

California Bar No. 184562

R. Scott Oswald, Esq. (to be admitted *pro hac vice*)

soswald@employmentlawgroup.com

The Employment Law Group, P.C.

888 17th Street, NW, Suite 900

Washington, D.C. 20006

(202) 261-2806

(202) 261-2835 (facsimile)

Mark Kleiman, Esq.

Law Office of Mark Allen Kleiman

mkleiman@quitam.org

2907 Stanford Avenue

Venice, California 90292

310-306-8094

IN THE UNITED STATES DISTRICT COURT
FOR THE CENTRAL DISTRICT OF CALIFORNIA
WESTERN DIVISION

[UNDER SEAL],

Plaintiff,

v.

[UNDER SEAL],

Defendants.

CASE NO.: CV 13-5861 GHK(AJWx)

SECOND AMENDED
COMPLAINT FOR VIOLATIONS
OF THE FEDERAL FALSE
CLAIMS ACT AND STATE
FALSE CLAIMS ACTS

FILED UNDER SEAL (Pursuant to
31 U.S.C. § 3729 False Claims Act)

JURY TRIAL DEMANDED

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006

Ph: 202.331.2883 • Fax: 202.261.2835

1 David L. Scher, Esq.
2 dscher@employmentlawgroup.com
3 California Bar No. 184562
4 R. Scott Oswald, Esq. (to be admitted *pro hac vice*)
5 soswald@employmentlawgroup.com
6 The Employment Law Group, P.C.
7 888 17th Street, NW, Suite 900
8 Washington, D.C. 20006
9 (202) 261-2806
10 (202) 261-2835 (facsimile)

11 Mark Kleiman, Esq.
12 Law Office of Mark Allen Kleiman
13 mkleiman@quitam.org
14 2907 Stanford Avenue
15 Venice, California 90292
16 310-306-8094

17
18 **IN THE UNITED STATES DISTRICT COURT**
19 **FOR THE CENTRAL DISTRICT OF CALIFORNIA**
20 **WESTERN DIVISION**

21 [UNDER SEAL],

22 Plaintiff,

23 v.

24 [UNDER SEAL],

25 Defendants.

CASE NO.: CV 13-5861 GHK(AJWx)

**SECOND AMENDED
COMPLAINT FOR VIOLATIONS
OF THE FEDERAL FALSE
CLAIMS ACT AND STATE
FALSE CLAIMS ACTS**

FILED UNDER SEAL (Pursuant to
31 U.S.C. § 3729 False Claims Act)

JURY TRIAL DEMANDED

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006

Ph: 202.331.2883 • Fax: 202.261.2835

David L. Scher, Esq.
dscher@employmentlawgroup.com
 California Bar No. 184562
 R. Scott Oswald, Esq. (to be admitted *pro hac vice*)
soswald@employmentlawgroup.com
 The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 (202) 261-2806
 (202) 261-2835 (facsimile)

Mark Kleiman, Esq.
 Law Office of Mark Allen Kleiman
mkleiman@quitam.org
 2907 Stanford Avenue
 Venice, California 90292
 310-306-8094

**IN THE UNITED STATES DISTRICT COURT
 FOR THE CENTRAL DISTRICT OF CALIFORNIA
 WESTERN DIVISION**

UNITED STATES OF AMERICA *ex rel*
 MARIA GUZMAN,

STATE OF CALIFORNIA *ex rel*
 MARIA GUZMAN,

STATE OF DELAWARE *ex rel*
 MARIA GUZMAN,

DISTRICT OF COLUMBIA *ex rel*
 MARIA GUZMAN

CASE NO.: CV 13-5861 GHK(AJWx)

**SECOND AMENDED
 COMPLAINT FOR VIOLATIONS
 OF THE FEDERAL FALSE
 CLAIMS ACT AND STATE
 FALSE CLAIMS ACTS**

FILED UNDER SEAL (Pursuant to
 31 U.S.C. § 3729 False Claims Act)

JURY TRIAL DEMANDED

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006

Ph: 202.331.2883 • Fax: 202.261.2835

1 STATE OF FLORIDA *ex rel*
2 MARIA GUZMAN,
3
4 STATE OF GEORGIA *ex rel*
5 MARIA GUZMAN,
6
7 STATE OF HAWAII *ex rel*
8 MARIA GUZMAN,
9
10 STATE OF ILLINOIS *ex rel*
11 MARIA GUZMAN,
12
13 STATE OF INDIANA *ex rel*
14 MARIA GUZMAN,
15
16 STATE OF LOUISIANA *ex rel*
17 MARIA GUZMAN,
18
19 COMMONWEALTH OF
20 MASSACHUSETTS *ex rel*
21 MARIA GUZMAN,
22
23 STATE OF MICHIGAN *ex rel*
24 MARIA GUZMAN,
25
26 STATE OF MINNESOTA *ex rel*
27 MARIA GUZMAN,
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006

Ph: 202.331.2883 • Fax: 202.261.2835

1 STATE OF MONTANA *ex rel*
2 MARIA GUZMAN,
3
4 STATE OF NEVADA *ex rel*
5 MARIA GUZMAN,
6
7 STATE OF NEW HAMPSHIRE *ex rel*
8 MARIA GUZMAN,
9
10 STATE OF NEW JERSEY *ex rel*
11 MARIA GUZMAN,
12
13 STATE OF NEW MEXICO *ex rel*
14 MARIA GUZMAN,
15
16 STATE OF NEW YORK *ex rel*
17 MARIA GUZMAN,
18
19 STATE OF NORTH CAROLINA *ex rel*
20 MARIA GUZMAN,
21
22 STATE OF OKLAHOMA *ex rel*
23 MARIA GUZMAN,
24
25 STATE OF RHODE ISLAND *ex rel*
26 MARIA GUZMAN,
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006

Ph: 202.331.2883 • Fax: 202.261.2835

1 STATE OF TENNESSEE *ex rel*

2 MARIA GUZMAN,

4 STATE OF TEXAS *ex rel*

5 MARIA GUZMAN,

7 COMMONWEALTH OF VIRGINIA

8 *ex rel* MARIA GUZMAN,

10 STATE OF WASHINGTON *ex rel*

11 MARIA GUZMAN,

13 Plaintiff,

14 v.

16 INSYS THERAPEUTIC, INC.;

17 MICHAEL BABICH, an Individual;

18 ALEC BURLAKOFF, an Individual;

19 JOHN N. KAPOOR, an Individual;

20 and DOES 2 through 15,

22 Defendants.

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

TABLE OF CONTENTS

PAGE

INTRODUCTION.....	1
JURISDICTION AND VENUE	3
PARTIES.....	4
FACTUAL ALLEGATIONS	7
Work History and INSYS’s Hiring Strategies.....	7
The INSYS Business Model and Kickbacks to Doctors	12
Kickbacks and Speaker Programs	14
Strip Clubs, Shooting Ranges, Meals, and Referrals.....	17
Hiring a Doctor’s Significant Other Family Member, or Friend	22
Burlakoff Offered Physicians Lucrative Business Deals and Partnerships...	24
Instructions for Avoiding Anti-Kickback Standards.....	24
SUBSYS’s Indication and Usage, and INSYS’s Off-Label Marketing	27
The IRC and Prior Authorization	33
Instructing Sales Representatives to Market for Off-Label Uses.....	34
Targeting Doctors Who are Not Oncologists or Pain Specialists	38
INSYS’s Off-Label Marketing Results in Doctors Prescribing SUBSYS For Contraindications, Off-Label Use, and Over Titrating	40
Prescriptions for Contraindications	41

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1	Prescriptions for Off-Label Uses	42
2	Falsification of Documents to CMS	45
3		
4	Switching Patients from Atiq Indicates the Large Number of Medicare	
5	and Medicaid Patients being Prescribed SUBSYS.....	46
6	Titration and Over-Prescribing	48
7	COUNT I: False Claims Act Violations	52
8		
9	COUNT II: Off-Label Dissemination Violations.....	55
10	COUNT III: Medicaid Non-Approved Use Violations	57
11	COUNT IV - Medicare Non-Approved Use Violations.....	59
12		
13	COUNT V – Violation Of The California False Claims Act 12651(a)(1)	62
14	COUNT VI - Violation Of The California False Claims Act (12651(a)(2)	64
15		
16	COUNT VII - Violation Of The California False Claims Act (12651(a)(3).....	65
17	COUNT VIII - Violation Of The California False Claims Act (12651(a)(7)	66
18	COUNT IX – Delaware False Claims And Reporting Act (“DFCA”).....	67
19		
20	COUNT X - District Of Columbia False Claims Act.....	69
21	COUNT XI - Violation Of The Florida False Claims Act	71
22		
23	COUNT XII - Violation Of The Georgia False Medicaid Claims Act.....	73
24	COUNT XIII - Hawaii False Claims Act	74
25		
26	COUNT XIV - Illinois Whistleblower Reward And Protection Act.....	75
27	COUNT XV - Violation Of The Indiana False Claims Act	77
28		

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1	COUNT XVI - Violation Of The Louisiana Medical Assistance	
2	Programs Integrity Law	79
3	COUNT XVII - Violation Of The Massachusetts False Claims Act.....	84
4	COUNT XVIII - Violation Of The Michigan Medicaid False Claims Act.....	85
5		
6	COUNT XIX - Violation Of The Minnesota False Claims Act	87
7	COUNT XX - Violation Of The Montana False Claims Act	89
8		
9	COUNT XXI - Violation Of The Nevada False Claims Act.....	91
10	COUNT XXII - Claims Of The State Of New Hampshire Violation Of The New	
11	Hampshire False Claims Act.....	92
12	COUNT XXIII - Violation Of The New Jersey False Claims Act.....	94
13		
14	COUNT XXIV - Violation Of The New Mexico Medicaid False Claims Act And	
15	The New Mexico Fraud Against Taxpayers Act.....	97
16	COUNT XXV - Violation Of The New York False Claims Act.....	99
17	COUNT XXVI - Violation Of The North Carolina False Claims Act.....	101
18		
19	COUNT XXVII - Violation Of The Oklahoma False Claims Act.....	103
20	COUNT XXVIII - Violation Of The State False Claims Act (Rhode Island).....	106
21	COUNT XXIX - Violation Of The Tennessee Medicaid False Claims Act	108
22		
23	COUNT XXX - Violation Of The Texas Medicaid Fraud Prevention Act.....	110
24	COUNT XXXI - Violation Of Virginia Fraud Against Taxpayers Act	114
25		
26	COUNT XXXII - Violation Of The Washington State Medicaid	
27	Fraud False Claims Act.....	116
28	COUNT XXXIII - Illegal Retaliation in Violation of Federal False Claims Act..	118

COUNT XXXIV - Illegal Retaliation in Violation of Florida False Claims Act...	119
COUNT XXXV - Illegal Retaliation in Violation of Public Policy	120
PRAYER FOR RELIEF.....	121
DEMAND FOR JURY TRIAL.....	124

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

Introduction

1
2 1. Qui tam relator Maria Guzman (“Guzman”), by her attorneys,
3
4 individually and on behalf of the United States of America, files this complaint
5 against INSYS Therapeutics, Inc. (“INSYS”) to recover damages, penalties, and
6 attorneys’ fees for violations of the federal False Claims Act, 31 U.S.C. §§ 3729 et
7 seq., (“FCA” or “False Claims Act”).
8

9 2. INSYS instituted a kickback-fueled off-label marketing campaign to
10 induce doctors to prescribe INSYS’s drug SUBSYS, a powerful opioid agonist drug
11 that stimulates activity at opioid receptors in the central nervous system normally
12 stimulated by naturally occurring opioids. SUBSYS is a fentanyl product, in the
13 opioid agonist family with such other drugs as morphine, oxycodone, and heroin. As
14 a result of the off-label campaign and egregious financial kickbacks, SUBSYS is
15 being marketed and prescribed far beyond its stated indication, which is limited to
16 breakthrough cancer pain only, at a beginning dosage of 100 micrograms.
17
18

19 3. The FDA has contraindicated SUBSYS for several uses due to the risk
20 of overdose and requires enrollment in a special program in order to prescribe this
21 potent and addictive drug. INSYS’s off-label campaign, which includes the kiss of
22 death message, which encourages doctors to quickly titrate patients, has resulted in at
23 least one pharmacist contacting the relator to ask her to return a patient to a lower,
24 safer dosage. INSYS off-label marketing and financial inducements have been
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 successful as many doctors write SUBSYS for contraindicated and off-label uses in
 2 Medicare and Medicaid patients, including for postoperative pain and back pain,
 3 which is counter to FDA warnings of respiratory failure and death. INSYS also
 4 utilizes a mail order pharmacy that sends SUBSYS to patients who had not requested
 5 the drug and that does not properly instruct patients on the storage of SUBSYS,
 6 which can lead to children fatally ingesting the drug.
 7

8
 9 4. INSYS instituted programs throughout the country to induce doctors to
 10 prescribe SUBYS over those of competitors by means of monetary payments, trips to
 11 strip clubs and shooting ranges, stock options, hiring physician's significant others,
 12 and expensive meals in violation of federal anti-kickback laws. One physician, Dr.
 13 Stuart Krost, was promised a \$100,000 payment for this "support with SUBSYS" and
 14 INSYS spent \$58,000 on meal expenses for doctors in just one month. INSYS,
 15 focusing on increasing its market share and generating high revenues, disregarded
 16 patient well-being, such as sending congratulatory emails to sales representatives that
 17 state, "Cha Ching again!" when a patient is prescribed SUBSYS for \$40,000. INSYS
 18 has increased profits enough to publicly trade SUBSYS, earning \$36 million in gross
 19 proceeds from the sale of 4.6 million shares in May 2013. Many of the INSYS
 20 executives have stock options for hundreds of thousands of dollars.
 21

22 5. INSYS also maintains a work environment in which the male-dominated
 23 executive and management team frequently sexually treat female doctors who fail to
 24
 25
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 prescribe “enough” SUBSYS in exchange for their kickbacks from INSYS with
 2 blatant disrespect, best summarized in a text message from INSYS Vice President of
 3 Sales Alec Burlakoff, in a text message to the Relator regarding a female doctor in
 4 her territory: “She fuckn sucks kock mia! What else can I say! XOXOXO...I hate
 5 that stupid bitch – dr banchik!!!!!! I want to jerk off in her fuckn face! Joe would
 6 jerk off in her face, but his dick is too tiny for him to grab.” The same attitudes and
 7 behavior were used harass female sales representatives.

8
 9
 10
 11 6. In connection with the filing of this original Complaint, Relator has
 12 furnished the United States with substantially all material evidence and information
 13 in Relator’s possession.
 14

15 **Jurisdiction and Venue**

16 7. This Court has subject matter jurisdiction over this action under 31
 17 U.S.C. §§ 3730 and 3732.
 18

19 8. This Court has personal jurisdiction over the Defendants pursuant to 31
 20 U.S.C. § 3732 (a) because the Defendant transacts business in this judicial district.
 21

22 9. Venue is proper in this District pursuant to 31 U.S.C. § 3732 (a) and
 23 under 28 U.S.C. § 1391(c) because the Defendant transacts business in this judicial
 24 district.
 25
 26
 27
 28

Parties

10. Relator Maria Guzman is a citizen of the United States and a resident of Clayton, North Carolina.

11. Relator resided in Florida until June 2013.

12. Guzman began working for INSYS in January 2012 as a Specialty Sales Professional and was fired in July of 2013.

13. At all times material hereto, John N. Kapoor was the Founder and Executive Chairman of INSYS, and held the majority of its shares. He exercised his authority to direct and control many of the activities described herein. Kapoor was adamant that doctors selected for the speakers program be actively prescribing Subsys. In addition, Kapoor was aware of and supported the sales initiative to push doctors to prescribe 400 mcg only instead of 100 or 200 mcg doses.

14. At all times material hereto, Michael Babich was the Chief Executive Officer of INSYS, and exercised his authority to direct and control many of the activities described herein.

15. Michael Babich has served as President since November 2010 and was appointed Chief Executive Officer in March 2011. From March, 2007 until his appointment as President of INSYS Therapeutics. Babich was Chief Operating Officer and a Director of INSYS Pharma, Inc., a wholly owned subsidiary. He had

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 previously worked at EJ Financial Enterprises, Inc., a venture capital firm founded by
2 Defendant Kapoor.

3
4 16. Alec Burlakoff was originally hired by INSYS as a regional sales
5 manager but in September of 2012, was quickly promoted to national Vice-President
6 of Sales, where he exercised his authority to direct and control many of the activities
7 described herein
8

9
10 17. Before coming to sell INSYS' opioid, Burlakoff had been previously
11 employed selling opioids for Cephalon, which plead guilty to criminal charges for the
12 illegal marketing of the opioid Actiq. To illegally market Actiq, Cephalon had its
13 sales representatives (a) call on physicians who would not normally prescribe the
14 drugs in the course of their practice; (b) prompt the doctors to initiate conversations
15 about off-label uses; (c) tell doctors how to document their off-label uses to get the
16 drugs paid for by Medicare, Medicaid, and private insurers; and (d) send the doctors
17 to lavish "consultant" meetings. Cephalon also underpaid its sales representatives,
18 and then offered them sizeable sales-based bonuses to encourage off-label sales.
19
20
21

22 18. Burlakoff helped manage Cephalon's sales of Fentora, a fentanyl-based
23 drug that Cephalon sold after the Actiq scandal broke, and adopted Cephalon's
24 criminal marketing strategies when he moved to INSYS.
25

26 19. Defendant INSYS Therapeutics, Inc. is a specialty pharmaceutical
27 company headquartered at 444 South Ellis Street, Chandler, Arizona, 85224.
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 20. INSYS is incorporated in Delaware at 1209 Orange Street, City of
2 Wilmington, County of New Castle, Delaware, 19801.

3
4 21. Relator is informed and believes and based thereon alleges that each of
5 the entities identified as Does 1-15, inclusive, were the employers, agents,
6 contractors, directors, or otherwise responsible for the acts alleged herein. Their
7 identity is unknown at this time and will be set forth later when it is known.
8

9 22. INSYS has two marketed products: SUBSYS and Dronabinol SG
10 Capsule, and is awaiting approval for Dronabinol Oral Solution.
11

12 23. SUBSYS is a fentanyl sublingual spray: a proprietary, single-use
13 product that delivers fentanyl, and opioid analgesic, in seconds for transmucosal
14 absorption under the tongue.
15

16 24. Transmucosal immediate-release fentanyl ("TIRF") products generated
17 \$440 million in U.S. sales in 2010 and INSYS believes this market has the potential
18 to expand with its faster-acting fentanyl product, SUBSYS.
19

20 25. In March 2011, INSYS submitted a New Drug Application to the Food
21 and Drug Administration ("FDA") for Fentanyl SL Spray for the treatment of
22 breakthrough cancer pain in opioid-tolerant patients.
23

24 26. The FDA approved SUBSYS for the limited use of relieving
25 breakthrough cancer pain, which is characterized by sudden, often unpredictable,
26 episodes of intense pain that can peak in severity despite pain medication.
27
28

1 27. SUBSYS was approved for sale on January 5, 2012 and was made
2 publicly available on March 26, 2012.

3 28. On May 7, 2013, 5 days after its initial public offering of common stock,
4
5 INSYS closed the offering as all 4,600,000 shares had been sold, with aggregate
6 gross proceeds of \$36.8 million.

7 29. INSYS's Executive Team is comprised of three men and the INSYS
8
9 Board of Directors has seven male members; there are no females on the Executive
10 Team or the Board and very few female managers.

11 30. The absence of women in leadership roles at INSYS contributes to the
12
13 rampant sexual harassment and the hostile work environment for its female
14 employees, including sales representatives experiencing unwanted flirtatious
15 comments from executives and management sending sexually explicit text messages
16 to female members of their sales team.

17 31. The INSYS Code Conduct states that, "INSYS values a work
18
19 environment that is free of any form of harassment...[which] can included
20 unwelcomed sexual conduct, threats or offensive comments."

21
22
23 **FACTUAL ALLEGATIONS**

24 **Work History and INSYS's Hiring Strategies.**

25 32. In January 2012, Guzman began working for INSYS as a Specialty Sales
26
27 Professional.
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 33. Guzman remains on the INSYS South East Region sales team, with her
2 territory in the West Palm Beach area of Florida.

3
4 34. Before serving as a sales representative for SUBSYS, Guzman did not
5 possess any pharmaceutical sales experience: Guzman earned her Bachelor's degree
6 in Education and Dance, worked for G&K Services (a company that provides work
7 uniforms), and was a Marketing Associate for Corporate Counseling Associates.

8
9 35. INSYS hiring individuals without pharmaceutical experience as sales
10 representatives serves as a standard practice for the company.

11
12 36. INSYS Specialty Sales Professionals who lack previous pharmaceutical
13 experience are unfamiliar with compliant marketing standards.

14
15 37. In or around late 2012, INSYS hired Lillian Logatti, a dental hygienist
16 who lacked pharmaceutical sales experience, as a South East Region sales
17 representative.

18
19 38. INSYS apparently hired Logatti to have sexual relations with doctors in
20 exchange for SUBSYS prescriptions, which has been implied by INSYS management
21 and employees, through statements such as one in which Joe Rowan, the Southeast
22 Regional Sales Manager told Dr. Bart Gatz that she (Logatti) was as dumb as rocks,
23 but that she was sleeping with another doctor and getting a lot of prescriptions out of
24 him." During the April 2013 National Sales Conference Rowan publicly stated that
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 Logatti had been “out there working it” in regards to forming relationships with her
2 doctors.

3
4 39. Aside from recruiting individuals who lack pharmaceutical sales
5 experience, INSYS has also hired many former Cephalon, Inc. employees. One such
6 employee was Karen Hill, who became Insys’ national trainer for sales and actively
7 promoted Insys’ aggressive off label marketing strategy.
8

9 40. On or around September 29, 2008, the Department of Justice (“DOJ”)
10 announced a \$435 million settlement to resolve off-label marketing claims relating to
11 Actiq, a TIRF product, and two other drugs.
12

13 41. On or around September 29, 2008, the DOJ stated that \$375 million of
14 the plea agreement was to resolve False Claims Act allegations arising from claims to
15 Medicaid, Medicare, and other federal programs.
16

17 42. Like the SUBSYS label, the Actiq label stated that the drug was for
18 opioid tolerant cancer patients with breakthrough cancer pain, to be prescribed by
19 oncologists or pain specialists familiar with opioids.
20

21 43. Cephalon utilized the mantra “pain is pain,” and instructed Actiq sales
22 representatives to focus on physicians other than oncologists and to promote Actiq
23 for uses other than breakthrough cancer pain.
24

25 44. INSYS employees also promote this motto and target doctors other than
26 oncologists.
27
28

1 45. In December 2011, INSYS hired Matt Napoletano (“Napoletano”), a
2 former Cephalon executive who led the launch for several of its pain products, as its
3 Vice President of Marketing.
4

5 46. In or around November or December 2012, INSYS hired former
6 Cephalon employee Dan Tondre (“Tondre”) as a Specialty Sales Professional.
7

8 47. During a conference call in late 2012 or early 2013 with other Special
9 Sales Professionals and managers, Tondre described how he sold INSYS drugs to
10 doctors, stating that, “Pain is pain. It does not matter whether it is back pain or a
11 migraine. Pain is pain and SUBSYS treats pain.”
12

13 48. INSYS management frequently has praised Tondre for his success at
14 Cephalon and has instructed other sales representatives to follow his lead in the
15 marketing of SUBSYS.
16

17 49. In December 2012, Rowan sent a text message to the South East Region
18 sales team congratulating Tondre for making a 1200 mcg SUBSYS sale and then
19 stating that Tondre was “asking for the business wow...it works...let’s get them
20 Southeast.”
21

22 50. INSYS has hired other former Cephalon employees, many of whom
23 handled marketing for that company, including Vice President of Sales Alec
24 Burlakoff, Specialty Sales Professional and National Trainer Karen Hill, Specialty
25 Sales Professional and Regional Sales Manager for the South East Region Joseph
26
27
28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 Rowan, Specialty Sales Professional and Regional Trainer Nannette Alonzo, Specials
 2 Sales Professional Marcus Seiferith, and Medical Marketing Communications Senior
 3 Manager Desiree Hollandsworth.
 4

5 51. INSYS has comprised a team of employees who have either been
 6 recruited from a pharmaceutical company that settled a multi-million dollar off-label
 7 marketing lawsuit or individuals without any pharmaceutical sales experience or
 8 familiarity with compliant marketing standards.
 9

10 52. Babich has actually praised the hiring strategy, stating “The majority of
 11 our sales reps have no prior pharmaceutical experience. We think that is very
 12 important from the perspective of “they are out there delivering a message.”
 13

14 53. Burlakoff effected and supported Babich’s marketing strategy. INSYS,
 15 for example, hired Sunrise Lee, a former dancer at a Florida strip club as a sales
 16 executive. Sunrise also managed an escort service and had no academic degree.
 17 Burlakoff defended the decision, claiming “Doctors really enjoyed spending time
 18 with her and found Sunrise to be a great listener.” “She’s more of a closer”, he
 19 added praising her “empathy”.
 20

21 54. Babich also established a compensation system certain to induce
 22 misbehavior. Under Babich, INSYS established sales force incentives which
 23 completely reverse the pharmaceutical industry compensation manual. Although
 24 typical pharmaceutical reps earn salaries in the \$80-90,000 range with a potential for
 25
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 \$30-40,000 in bonuses, Subsys reps earn only \$40,000 in salary with a potential
 2 \$72,000 in bonuses. Babich boasted that Subsys' 38% sales growth between the
 3 third quarter and the fourth quarter of 2013 was "strong testimony to the success of
 4 this approach."
 5

6 55. Babich's carrot was paired nicely with Burlakoff's stick. Burlakoff
 7 frequently threatened to fire any sales representative who didn't get at least one new
 8 prescription written every day.
 9

10 56. INSYS also established relationships with and speaker programs for
 11 former Cephalon prescribers, including Doctor Stuart Krost ("Dr. Krost"), Doctor
 12 Bart Gatz ("Dr. Gatz"), and Doctor Lisa Banchik ("Dr. Banchik").
 13

14 **The INSYS Business Model and Kickbacks to Doctors.**

15 57. After Burlakoff arrived, the speaker program became an overt kickback
 16 program sometimes with just the doctor and one attendee. Relator is informed and
 17 believes and based thereon alleges that Burlakoff told the sales staff that the purpose
 18 of the speaker's program was to "put money into the pockets" of doctors
 19

20 58. Under Burlakoff, the INSYS business model consists of providing
 21 doctors with substantial compensation – including, stock options, strip club trips, and
 22 hiring physicians' significant others – so that the doctor then returns the "favor" to
 23 the sales representative by prescribing SUBSYS. One physician was even offered
 24 \$100,000 in payments.
 25
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

59. In or around March 2013, National Trainer Karen Hill created a PowerPoint presentation (“2013 PowerPoint”) for Specialty Sales Professionals which illustrates the centrality of payoffs, such as instructing representatives to target Drs. Lee and Arcila for more lucrative speaking opportunities and stating that Drs. Kornick, Kramarich, and Khanna will be paid through more preceptorships (which usually entail allowing a representative to shadow the doctor but which INSYS is using as another marketing tool).

60. The 2013 PowerPoint contains several pictures of doctors out drinking with INSYS staff.

61. The 2013 PowerPoint outlines what “hot buttons” representatives should utilize with doctors, such as “\$” and “hanging out.”

62. The 2013 PowerPoint provides “special notes” about the doctors and ways to increase sales with them such as “loves to party.”

63. The 2013 PowerPoint highlights “challenges” that representatives will face with some of the doctors such as “very conservative and cautious...continue challenging her thinking” as well as “potential” with some physicians, such as “good with increasing strengths.”

64. In July 2012, Vice President for Sales Alec Burlakoff sent a text message to Guzman stating, “I know pedro [Dr. Charles Huang’s physician’s

1 assistant] very well also...He's the one who probably writes the most. Let's take
 2 pedro out for some fun! I bet you he would LOVE to smoke with us!"

3
 4 65. INSYS's tactics have resulted in doctors recommending and writing
 5 SUBSYS prescriptions for their patients, including those on Medicare and Medicaid,
 6 in exchange for kickbacks, and often times switching patients from Actiq, SUBSYS's
 7 competitor.
 8

9
 10 **Kickbacks and Speaker Programs.**

11 66. One of the primary ways INSYS provides doctors with kickbacks for
 12 prescribing SUBSYS is through its speaker programs.
 13

14 67. INSYS speaker programs consist of the doctors giving presentations to
 15 others regarding their experience with SUBSYS and in return they receive a speaker
 16 fee.
 17

18 68. INSYS officially states that speaker programs are based on clinical
 19 experience, and not on the amount of SUBSYS the doctor prescribes. However, John
 20 Kapoor, INSYS' founder and executive chairman, instructed Burlakoff that Subsys
 21 speakers should support and show belief in the product or they would have to be
 22 removed from the speaker program. This support and belief was evidenced by high
 23 prescriptions.
 24
 25

26 69. In July 2012, Burlakoff sent a text message to several sales
 27 representatives in which he stated "we have done all these programs and we are flat
 28

1 in sales...Are our speakers doing their part...We must hold our speakers accountable,
 2 programs are going to begin to get cancelled very quickly...Clearly, we have done a
 3 poor [job] setting proper expectations for our speaker.”
 4

5 70. In July 2012, Burlakoff sent Guzman a text message stating, “Don't
 6 worry about Dr Banchik or Dr Vendrys's speaking abilities. They do not need to be
 7 good speakers, they need to write a lot of Subsys.”
 8

9 71. In December 2012, Burlakoff sent the following text message: “Mia -
 10 just wanted to make sure you know that Dr Banchik is taking you for a ride. She
 11 doesn't produce shit for units or dollars. She needs to understand you can't keep
 12 giving her programs, when gatz has truly earned them! Show her the numbers!”
 13
 14

15 72. During the April 2013 conference, Rowan explained how he would like
 16 the speaker program ran, instructing representatives not to take doctors to Ruth's
 17 Chris Steakhouse or other expensive restaurants because he did not want a large
 18 amount of money spent on “dipshits that aren't going to write,” but would rather keep
 19 that money in the budget to spend on other doctors for “better uses.”
 20
 21

22 73. The INSYS Code of Conduct states that the company must “monitor all
 23 fees, payments, and compensation paid for advisory, consulting or other services to
 24 avoid even the appearance of inappropriate influence.”
 25

26 74. The INSYS Certificate of Compliance states, “INSYS has established an
 27 annual spending limit of \$1,500 on meals and educational items which may be
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 provided to a healthcare professional.” Fees from services to such healthcare
2 professionals are excluded from this amount but are always based on fair market
3 value...items of nominal value (less than \$10) or financial support for educational
4 programs are also exempt from this amount.”

6 75. In April 2013, Burlakoff sent Dr. Krost a text message in April 2013
7 which stated, “Dr. Krost...I know it[']s not a lot to you, but I can commit to 100K to
8 you via speaker programs or meals toward your restaurant. We don’t need the food,
9 just charge our card and give [a]s an itemized receipt. Just need your support on
10 subsys.”

13 76. In October 2012, Burlakoff sent Guzman a text message and an email
14 stating that Dr. Krost would earn \$1,600 per program and that INSYS would hold all
15 of Dr. Krost’s programs in the restaurant he owns, to persuade him to switch his
16 Aqtiq patients to SUBSYS.

19 77. In October 2012, Burlakoff indicated to Guzman in a text message that
20 INSYS would pay Dr. Gatz \$750 per hour for trainings conducted via telephone.

22 78. In December 2012, Burlakoff sent Guzman a text message stating that
23 INSYS paid Dr. Gatz \$36,000 in one quarter for speaker programs.

25 79. The doctors affiliated with INSYS participate in the speaker programs
26 because of the substantial payments and kickbacks they receive, rather than their
27 belief in the benefit of the drug for cancer patients.
28

1 80. In September 2012, Burlakoff sent Guzman a text message indicating
2 that "I think dr krost would want to speak, he loves money."

3
4 81. On August 16, 2012, Dr. Banchik sent a text message to Guzman
5 thanking her for a "fun night" and stating "I just wish I had more MD'S that can
6 write it themselves but these people will refer to me to write it for them."

7
8 82. In 2012, Dr. Banchik received speaker fees and referrals from
9 participating in the INSYS speaker programs, and because she then obtained more
10 patients through these referrals, she was able to prescribe more SUBSYS and in
11 return earn more speaker programs and fees from INSYS.

12
13 83. In September 2012, Dr. Banchik indicated how important these speaker
14 fees to her when she sent a text message to Burlakoff asking why INSYS had failed
15 to pay her for her program, stating, "I am not happy Alec."

16
17 84. In September 2012, Dr. Gatz sent Guzman an email inquiring about
18 when he would be paid the \$7,200 he was offered for three speaker programs in
19 which he participated, as his honoraria check had been lost.

20
21
22 **Strip Clubs, Shooting Ranges, Meals, and Referrals.**

23
24 85. In addition to the program speaker fees that doctors receive for
25 prescribing SUBSYS, INSYS also provides doctors with other kickbacks.
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 86. On or around Friday, January 18, 2013, Burlakoff and Rowan treated Dr.
2 Gatz to a strip club visit, where they purchased him two \$500 private champagne
3 room sessions, to ensure he continued prescribing SUBSYS.
4

5 87. On or around January 19, 2013, Burlakoff sent Guzman a text message
6 expressing that it “[w]ent fantastic last night. Bart and I got back around 4 am.”
7

8 88. Shortly after January 18, 2013, Rowan sent Dr. Gatz a text message
9 stating, “Dr. Gatz, we appreciate you more than you could believe....Leaving that
10 meeting Alec and I felt very confident and what was going to happen....And you
11 show loyalty to us like no other...You need anything at all, it is done.”
12

13 89. Dr. Gatz responded to Rowan’s text message in January 2013 with,
14 “Thank you for the best weekend in years!!!”
15

16 90. The strip club visit resulted in an increase in prescription volume, as
17 Guzman reported to Burlakoff and Rowan on Wednesday, January 23, 2013, just five
18 days later, that Dr. Gatz had already written 17 SUBSYS prescriptions in three days.
19

20 91. Under the its Code of Conduct, the \$1,000 INSYS spent for private
21 champagne room sessions would not qualify as payment for an advisory services
22 from Dr. Gatz nor would it qualify as gift of less than \$100 designed for the patient or
23 for educational purposes; it would fall under the category of prohibited recreational
24 activity.
25
26
27
28

1 92. INSYS has also provided Dr. Gatz with many expensive dinners, stock
2 options, lunches for his office, and a trip to a shooting range, which serves as part of
3 a company-wide scheme to both encourage doctors to, and reward them for,
4 prescribing SUBSYS.

5
6 93. From on or about July 2 to July 10, 2012, Dr. Gatz prescribed 120 units
7 of SUBSYS.
8

9 94. On July 18, 2012, Burlakoff instructed Guzman in a text message that
10 she could take Dr. Gatz and “whoever out,” and that he would supply his credit card
11 number for the dinner.
12

13 95. From on or about July 23 to July 30, 2012, Dr. Gatz prescribed a total of
14 300 SUBSYS units.
15

16 96. On or about October 10, 2012, INSYS provided Dr. Gatz’s office with
17 lunch.
18

19 97. From on or about October 16 to October 30, Dr. Gatz wrote
20 prescriptions for 720 units of SUBSYS.
21

22 98. In or around November 2012, Rowan suggested that INSYS send top
23 prescribing doctors Thanksgiving dinners. Thanksgiving dinners were provided to
24 Dr. Gatz’ entire office staff. Insys correspondingly increased spending limits on sales
25 representatives’ charge cards to cover this additional expense.
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 99. During the April 2013 Arizona conference, Rowan and his South East
2 Region sales team acknowledged how successful these meals were and, in particular,
3 how Dr. Gatz's Office Manager ensured that prior authorizations were completed
4 after the meals were delivered.
5

6 100. A January 2013 report sent to INSYS sales representatives indicates
7 that the company spent over \$58,000 on meal expenses for doctors, with Rowan and
8 Burlakoff spending a total of approximately \$15,000.
9

10 101. The INSYS Code of Conduct states that "[m]eals may occasionally be
11 provided to HPCs [health care professionals] so long as they are modest and shared at
12 a reasonable location that is conducive to discussing educational information."
13

14 102. The INSYS Certificate of Compliance specifies that "INSYS has
15 established an annual spending limit of \$1,500 on meals" per provider.
16

17 103. The Compliance Guidance for Pharmaceutical Manufacturers states that
18 "entertainment, recreation, travel, meals and other benefits...potentially implicate the
19 anti-kickback statute if any one purpose of the arrangement is to generate business for
20 the pharmaceutical company."
21

22 104. The INSYS Code of Conduct states that the company must "monitor all
23 fees, payments, and compensation paid for advisory, consulting or other services to
24 avoid even the appearance of inappropriate influence."
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 105. In the January 2013 email containing the expense report, Burlakoff
2 stated that the representatives with the highest meal expenses should be ranked
3 number one in their region and obtaining a “return on investment.”
4

5 106. From on or about January 24 to February 5, 2013, Dr. Gatz prescribed a
6 total of 670 SUBSYS units.
7

8 107. On or about February 5, 2013, Rowan sent text messages to Dr. Gatz
9 and Guzman asking, “Would you like to get a bite to eat? Somewhere spectacular!
10 Maybe shoot guns before?”
11

12 108. On or about February 19, 2013, Rowan took Dr. Gatz to the shooting
13 range.
14

15 109. From on or about February 19 to March 7, 2013, Dr. Gatz prescribed a
16 total of 1010 units of SUBSYS.
17

18 110. On or about March 11, 2013, Rowan sent Dr. Gatz a text message
19 stating that he would take Dr. Gatz out to dinner anywhere he wanted, so that they
20 could “eat and celebrate life.”
21

22 111. INSYS also celebrated Dr. Gatz’s loyalty in recommending SUBSYS by
23 providing him with stock option.
24

25 112. In early 2013, Dr. Gatz had a conversation with Guzman regarding the
26 stock options INSYS had offered her and she ascertained from his excited tone and
27 knowledge of managing this particular stock that he was also receiving such options.
28

1 113. On February 19, 2013, Guzman's belief that Dr. Gatz was receiving
 2 stock was confirmed by a conversation that she heard between Rowan and Dr. Gatz
 3 while the three were out at the shooting range and dinner, a conversation in which
 4 Rowan told Dr. Gatz that "INSYS takes care of its people" and that "I [Rowan] have
 5 stock options, [Guzman] has stock options, and you will have stock options."

6
 7
 8 114. During the conversation regarding the stock options, Dr. Gatz also
 9 indicated that he would like a position with INSYS and a home in Arizona, and
 10 Rowan reiterated that "INSYS takes care of its people."

11
 12 **Hiring a Doctor's Significant Other Family Member, or Friend.**
 13

14 115. In addition to the monetary and meal kickbacks, INSYS also encourages
 15 doctors to subscribe SUBSYS by hiring their significant others or family members.
 16

17 116. On or around August 18, 2012 Burlakoff sent a text message to Dr.
 18 Charles Huang ("Dr. Huang") stating "I need to know if Paula [Dr. Huang's
 19 girlfriend] would take a full time job working for me? I also could use a few Subsys
 20 prescriptions. We have not seen anything, I want to have some fun!!! Can't do it w/o
 21 subsys scripts coming in at least once a day. Have Paula call me next week. Let's
 22 make it like the old days, turn the subsys switch on please Dr Huang!!...We mean
 23 what we say, just need you too (sic) get it going strong."
 24
 25
 26

27 117. From on or about August 21, 2012 to August 22, 2012, Dr. Huang
 28 prescribed 60 units of SUBSYS.

1 118. INSYS hired Dr. Huang's girlfriend, Paula, in or around fall 2012.

2 119. On or about March 28, 2013, Rowan asked Guzman if she could
3 recommend any sales representatives for the Nashville, Tennessee region, and stated
4 that the only qualification that INSYS required was that the individual was eighteen
5 years old and that he did not care if the person did not possess a college degree.
6
7

8 120. During the conversation regarding a Nashville sales representative on or
9 around March 28, 2013, Rowan told Guzman that the individual could be "anyone as
10 long as it was a doctor's girlfriend, son or daughter," and further that if the individual
11 were "banging a doctor, that would be perfect."
12

13 121. Relator is informed and believes and based thereon alleges that that
14 Burlakoff had personal knowledge of INSYS hiring other sales representatives at the
15 request of Subsys prescribers.
16
17

18 122. Babich engaged in the same misconduct. Relator is informed and
19 believes and based thereon alleges that Dr. Ruan in Mobile, Alabama promised
20 promised Babich that if Babich hired Joe Rowan as a sales representative, Dr. Ruan
21 would become the top prescriber of Subsys. Rowan was hired and assigned to Dr.
22 Ruan, who did indeed become a top prescriber of Subsys for certain periods. Dr.
23 Ruan's partner, Dr. Couch, was also a top Subsys prescriber and the two doctors had
24 ownership interest in a pharmacy that dispensed Subsys.
25
26
27
28

1 **Burlakoff Offered Physicians Lucrative Business Deals and Partnerships**

2 123. Relator is informed and believes and based thereon alleges that
3
4 Burlakoff personally offered Gawin Awerbuch, M.D., financial incentives, including
5 commissions based on the number of prescriptions and the strength of the dosage.
6 These illegal incentives triggered a prescription-writing spree which did not abate
7 until May of 2014 when Awerbuch was arrested for Medicare fraud and illegal
8 distribution of controlled substances. By then Awerbuch had written 1,283
9 prescriptions for Subsys for Medicare beneficiaries alone, costing Medicare nearly
10 seven million dollars.
11

12
13 124. Relator is informed and believes and based thereon alleges that
14
15 Burlakoff gave the manager of a multisite pain management clinic an annual
16 compensation package of \$73,000 for the manager's "contacts" while letting the
17 manager keep the INSYS job secret from the pain management clinic.
18

19 **Instructions for Avoiding Anti-Kickback Standards.**

20 125. Some INSYS managers and sales representatives were aware of the
21
22 illegality of using kickback schemes to obtain SUBSYS sales, particularly the former
23 Cephalon employees.
24

25 126. During the April 2013 INSYS conference in Arizona, management and
26 specialty sales professionals shared methods with one another on how to avoid anti-
27 kickback standards.
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 127. During the April 2013 conference, former Cephalon employee and
2 INSYS National Trainer Hill stated that she would have a “legit [speaker] program”
3 at an inexpensive restaurant where INSYS would provide her with \$100 to spend per
4 person, and she would use that budget to purchase wine and instruct the restaurant
5 staff to box the wine for the doctors to take home, remaining cautious as to how the
6 doctors left with the wine.
7

8
9 128. During a meeting at the April 2013 Arizona conference, Former
10 Cephalon employee and Manager Rowan stated that he is able to order beer, wine,
11 cigars, and expensive meats through his friend who owns a delicatessen, and that him
12 and another employee have been “doing this for years,” which is one of the reasons
13 he hired that employee.
14
15

16 129. After informing his sales team about his delicatessen owner friend at the
17 2013 conference meeting, Rowan then asked his representatives, “do you think he
18 runs it through as a cigar or a filet mignon? No. He runs it across as, you figure the
19 rest out.”
20
21

22 130. During the April 2013 meeting, Rowan indicated that the representatives
23 would receive more of a benefit from providing the doctor and his or her family with
24 some filet mignons and bottles of wine than by providing a lunch to the office.
25

26 131. During the 2013 conference meeting, Rowan stated that he used his
27 friend to order expensive products and then used them to encourage physicians to
28

1 prescribe SUBSYS, providing the example of how he inconspicuously placed a
2 cooler filled with filet mignons by Dr. Couch's desk and then told the doctor "thank
3 me later."
4

5 132. After Rowan described his methods for avoiding kickback standards
6 during the 2013 conference meeting, Hill instructed that the representatives should
7 get everything through a caterer, and that she had heard of other representatives
8 getting televisions for their doctors through a caterer.
9

10 133. After Hill's comments regarding obtaining items for doctors through
11 caterers during the April conference meeting, Rowan then told the South East Region
12 team, "I don't want to know what you do," but stated that they should do what they
13 need to, but "it's not on me."
14

15 134. During the April conference meeting, Rowan instructed his sales
16 representatives to "think outside of the box," and provided the example of going into
17 a restaurant during lunch, asking the staff to ring up a to-go receipt for ten people, but
18 then asking them to not provide the lunch but rather give the representative credit for
19 when they returned with the doctor and his or her spouse later that night for dinner.
20

21 135. After providing the example of how to treat doctors to dinner by
22 appearing to be within kickback standard limits during the April 2013 conference,
23 Rowan then told the representatives, "This is the shit we've done all of our careers."
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 But be smart about it, don't be a dipshit. I'm not forcing you to do this, but just
2 telling you this is what we do."

3
4 136. After explaining how he encouraged doctors to write SUBSYS
5 prescriptions by offering them filet mignons and dinners during the 2013 conference
6 meeting, Rowan explained "I don't think I did anything wrong because I did it with
7 food;" however, when one sales representative in the meeting began writing notes
8 regarding his methods, Rowan stated, "there is nothing to write down, just thinking
9 outside of the box."
10

11
12 **SUBSYS's Indication and Usage, and INSYS's Off-Label Marketing.**
13

14 137. INSYS developed methods for persuading doctors to prescribe SUBSYS
15 for contraindicated and off-label uses, which the FDA states can be deadly.
16

17 138. According to its label, the FDA indicated SUBSYS for the limited use of
18 management of breakthrough pain in adult cancer patients who are already receiving
19 and who are tolerant to around-the-clock opioid therapy for their underlying
20 persistent cancer pain.
21

22 139. Patients considered opioid tolerant are those who are taking around-the-
23 clock medicine consisting of at least 25 mcg of transdermal fentanyl/hour.
24

25 140. The FDA contraindicated SUBSYS for use in opioid non-tolerant
26 patients because life-threatening respiratory depression and death could occur in
27 patients not on a chronic regiment of opioids. For this reason, SUBSYS is
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 contraindicated in the management of acute or postoperative pain, including
2 headaches or migraines.

3
4 141. According to the label, the FDA intended that SUBSYS be used only in
5 the care of cancer patients and only by oncologists and pain specialists who are
6 knowledgeable of and skilled in the use of Schedule II opioids to treat cancer pain.

7
8 142. According to the label, the initial dose of SUBSYS to treat episodes of
9 breakthrough cancer pain is always 100 mcg.

10
11 143. According to the SUBSYS label, due to the potential for fatal overdose,
12 physicians should not convert patients on a mcg per mcg basis from any other
13 fentanyl product.

14
15 144. According to the SUBSYS label, death has been reported in children
16 who have accidentally ingested transmucosal immediate-release fentanyl products and
17 therefore SUBSYS must be kept out of the reach of children.

18
19 145. Due to the risk of misuse, abuse, addiction, and overdose, SUBSYS is
20 only available through a restricted program created by the FDA: the TIRF Risk
21 Evaluation and Mitigation Strategy (REMS) program.

22
23 146. INSYS has systematically violated and continues to violate every one of
24 these FDA indications and warnings

25
26 147. INSYS has created the “effective dosage message,” which continually
27 encourages sales representatives to push doctors to prescribe doses higher than 100
28

1 mcg and to quickly titrate patients to high levels because low SUBSYS dosages, as
 2 Babich states, are known as “the kiss of death.”

3
 4 148. Relator is informed and believes and based thereon alleges that
 5 Burlakoff personally trained representatives to use the off-label message that if
 6 patients had previously taken another Fentanyl product, the doctors should start
 7 patients on dosage levels higher than those indicated by the FDA because the FDA-
 8 approved starting dose might be insufficient. Burlakoff insisted that “everyone
 9 knows it doesn’t work at that level.”
 10

11
 12 149. Relator is informed and believes and based thereon alleges that the field
 13 training Burlakoff conducted via “ride alongs” differed markedly from their formal
 14 trainings, as Burlakoff recommended that doctors start patients on doses 400%
 15 greater than the FDA-approved starting dose, and that they move patients to doses
 16 800% and 1600% greater as quickly as possible.
 17

18
 19 150. Relator is informed and believes and based thereon alleges that Babich
 20 was fully aware of the financial advantage to INSYS of pushing patients to
 21 dangerously high dosage levels. For example, at a May, 2014 conference, he stated
 22 that “as patients stay on the drug longer, they have a tendency to move up in dose,
 23 making prescriptions more valuable as the patient stays on the drug . . .”
 24

25
 26 151. Relator is informed and believes and based thereon alleges that Kapoor
 27 yelled at sales representatives to get doctors to quickly move patients to higher doses,
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 and that he also pressured sales managers to start their patients on doses higher than
2 the FDA allowed.

3
4 152. Relator is informed and believes and based thereon alleges that at the
5 same April, 2014 sales meeting where Burlakoff told his sales staff to disregard his
6 previous instructions to push off-label uses and off-label dosage labels for Subsys, he
7 also warned the staff that anyone who discussed problems with doctors or patients in
8 an email would be fired.
9

10
11 153. INSYS has recently begun to rely on Linden Care Pharmacy, a mail
12 order pharmacy in New York, for its SUBSYS supply.
13

14 154. INSYS management promotes sales representatives and doctors to use
15 this pharmacy, as illustrated in a text message that Burlakoff sent to Guzman on or
16 around February 20, 2013, instructing her to, "Just use Linden care, they don't bitch."
17

18 155. In March 2013, Guzman became concerned about using this pharmacy
19 because a pharmacist in her territory, Doctor Brad Williams ("Dr. Williams") from
20 Family Care Pharmacy, told her in both a telephone conversation and email letter that
21 it was dangerous for SUBSYS to be distributed to patients through the mail as this
22 illustrated that a pharmacist had not properly educated the patient on storage and
23 disposal of the drug, which could result in children or pets accidentally ingesting and
24 overdosing on this powerful drug.
25
26
27
28

1 156. During the March 2013 telephone call with Guzman, Dr. Williams told
2 her that some of his patients had come into the pharmacy complaining that they had
3 not even ordered SUBSYS but that it had arrived through the mail at their homes.
4

5 157. During the March 2013 conversation with Guzman, Dr. Williams also
6 expressed his concern that medication crossing state lines from New York, where
7 Linden Care is located, to Florida, where his patients lived, violated state laws.
8

9 158. Guzman alerted Burlakoff to Dr. William's concern with the potential
10 risk to patient health and safety by utilizing a mail order pharmacy, but INSYS
11 continues to instruct sales representatives to use Linden Care.
12

13 159. During the April 2013 conference in Arizona, Liz Gurrieri ("Gurrieri")
14 from the Internal Reimbursement Center ("IRC") stated that representatives could
15 pre-populate their opt-in forms with Linden Care for the pharmacy section of the
16 form.
17

18 160. Relator is informed and believes and based thereon alleges that Babich
19 knew that only about 10% were for patients with a cancer diagnosis. The majority of
20 prescriptions were for patients with low back pain, sciatica, or peripheral neuropathy
21 secondary to diabetes. Babich observed this because he personally saw all of the
22 patients' diagnoses as they were funneled through the PA team, which was given
23 each patient's diagnosis and a list of drugs the patient had previously taken. It was so
24 unusual for the team to actually see a patient with a cancer diagnosis that they would
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 get excited. Babich, who remained in close personal contact with the PA team, was
2 aware of this..

3
4 161. Relator is informed and believes and based thereon alleges that
5 Burlakoff trained the Subsys sales force to “agree” with doctors that the drug was
6 good for any pain spike, whether or not it was for breakthrough cancer pain.
7

8 162. Relator is informed and believes and based thereon alleges that Babich
9 also, at a September, 2012 sales meeting, instructed the sales staff to give physicians
10 the off-label message that “breakthrough pain is the same as breakthrough cancer
11 pain”.
12

13 163. Relator is informed and believes and based thereon alleges that
14 Burlakoff would do “ride alongs”, where he accompanied sales representatives on
15 physician calls so he could teach them his illegal techniques, and that those
16 representatives with pharmaceutical industry experience were alarmed by what they
17 saw and heard Burlakoff do.
18
19

20 164. Relator is informed and believes and based thereon alleges that
21 Burlakoff personally trained representatives to use the off-label message that “pain is
22 pain”.
23
24

25 165. Relator and other employees observed and remarked that Babich and
26 Burlakoff were only interested in driving sales and making money by selling Subsys
27 to every kind of patient.
28

1 166. Relator is informed and believes and based thereon alleges that only
2 after law enforcement began scrutinizing INSYS' sales practices and Dr. Awerbuch's
3 Subsyst script-writing spree did Burlakoff, at an April, 2014 training session, tell the
4 sales representatives that they could no longer be doing what he had trained them to
5 do, thus admitting that they had been trained to market Subsyst illegally.
6
7

8 **The IRC and Prior Authorization.**
9

10 167. INSYS created the IRC in order to help doctors and patients obtain
11 approval for SUBSYS, including for off-label and contraindicated uses.
12

13 168. The IRC and physicians enter into agreements, in which the physician
14 provides patient information that the IRC then uses to complete prior authorization
15 forms.
16

17 169. INSYS utilizes Specialty Sales Professionals to gather patient
18 information and assist in receiving prior authorization. This includes instructing sale
19 representatives to review private patient information within doctors' offices.
20

21 170. The IRC handles appeals when prior authorization requests are denied.
22

23 171. The IRC occasionally issues "super vouchers" to patients while their
24 prior authorization and appeals are pending, which allows for free SUBSYS until
25 approval is obtained.
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 172. The IRC sometimes uses past and/or later-found instances of patients'
2 cancer diagnoses to obtain the Centers for Medicare and Medicaid Services ("CMS")
3 approval for the treatment of non-cancer pain.
4

5 173. On or around April 19, 2013, Gurrieri stated during an INSYS
6 conference presentation to the South East Region team that the IRC needs to know if
7 a patient had cancer in 1992 or if they have cancer – even if that is not what the
8 doctor is treating them for – because that cancer diagnosis is almost an assurance of
9 approval.
10

11 174. Gurrieri stated during the April 2013 presentation that patient face sheets
12 are important for the representatives to collect from the doctors because it is through
13 reading those forms that the IRC "finds cancer a lot of the time."
14

15 175. During the conference presentation, Gurrieri stated that INSYS is
16 "obviously promoting this on-label," but then went on to instruct the representatives
17 to ask doctors if the patient has a history of cancer and to ensure they include all
18 documentation for SUBSYS approval.
19
20
21

22 **Instructing Sales Representatives to Market for Off-Label Uses.**
23

24 176. INSYS engages in the off-label marketing of SUBSYS by encouraging
25 doctors to write prescriptions for conditions other than breakthrough cancer pain.
26
27
28

1 177. INSYS is careful to not include the promotion of off-label marketing in
2 official training material or emails, and recently warned employees during the April
3 2013 conference to keep questionable communications out of text messages.
4

5 178. INSYS nevertheless educates its sales representatives on how to
6 implement off-label marketing strategies during conference calls and in-person
7 meetings.
8

9 179. During the April 2013 conference in Arizona, Regional Sales Manager
10 Rowan told the South East Region team, "Don't be afraid of what we are indicated
11 for."
12

13 180. During this conference meeting on or around April 18, 2013, Rowan
14 asked his sales team to state the SUBSYS indication and the team responded it was
15 for breakthrough cancer pain. Rowan replied it was for breakthrough pain in cancer
16 patient, and he then stated "let's change that" and then stressed "pain" in his second
17 pronouncement of the indication.
18
19

20 181. Specialty Sales Professional Tondre then instructed the other
21 representatives during the conference meeting on or around April 18, 2013 to ask
22 their doctors if there was any difference in their patients having cancer or back pain,
23 and that if the patient ranks high on the pain scale, that "that's the whole point, pain
24 is pain."
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 182. The “pain is pain” mantra Tondre mentioned during the April
2 conference meeting was the same that he had used in an early 2013 conference call
3 where he stated “pain is pain, and SUBSYS treats pain;” this same mantra helped
4 prompt the DOJ to file a False Claims Act suit against Tondre’s previous employer,
5 Cephalon, as stated in the DOJ September 29, 2008 press release.
6

7
8 183. Sales Manager Rowan allowed Tondre to share his methods for
9 encouraging doctors to write off-label or contraindicated prescriptions without
10 interruption during the April 2013 conference meeting.
11

12 184. Later in the conference meeting on or around April 18, 2013, Rowan
13 instructed the team to call him if there were any issues that should not be put in
14 writing, such as associating speaker programs and fees with how many prescriptions
15 a doctor wrote.
16

17
18 185. During the conference meeting on or around April 18, 2013, Rowan told
19 his team that SUBSYS was great for sickle cell anemia, which is not a type of cancer.
20

21 186. In its September 29, 2008 press release regarding the FCA lawsuit
22 against Cephalon, the DOJ stated that promoting fentanyl products for sickle cell
23 anemia constituted off-label marketing.
24

25 187. During the conference meeting on or around April 18, 2013, former
26 Cephalon employee Hill instructed other representatives on the methods she utilized
27
28

1 on “how to throw something out to a doctor without sounding off-label,” such as
2 quoting another doctor.

3
4 188. After Hill stated that a representative could quote another doctor in order
5 to offer the off-label promotion of SUBSYS during the April 2013 conference
6 meeting, Rowan interjected and stated that this was not allowed because a
7 representative cannot use a third party to achieve off-label marketing.
8

9
10 189. After Rowan mentioned that using a third party to achieve off-label
11 marketing was not allowed during the April conference meeting, Hill then provided
12 an example of the conversation she would have with the doctor to get around this
13 requirement: “I was speaking to some of the other reps and their doctors are writing
14 for this, that, and the other. Do they have cancer? I don’t know, but they were
15 talking about sickle cell anemia.”
16

17
18 190. After Hill provided an alternative to “not sound off-label” when
19 encouraging doctors writing SUBSYS for conditions other than breakthrough cancer
20 pain during the April 2013 conference meeting, Rowan allowed Hill to instruct the
21 other representatives without interruption and did not indicate this method was
22 inappropriate; instead, Rowan stated shortly after that a doctor who writes SUBSYS
23 is not worried about its indication.
24

25
26 191. Following the conversation regarding how to encourage doctors to write
27 SUBSYS prescriptions for sickle cell anemia in the conference meeting on or around
28

1 April 18, 2013, a member of the South East sales team mentioned that doctors just
 2 want to hear the indication first, and then they are ready to listen to other uses,
 3 followed by Rowan adding that "If you want to talk science, you're going to suck."
 4

5 **Targeting Doctors who are Not Oncologists or Pain Specialists.**

6 192. INSYS has also pursued relationships with doctors who are not
 7 oncologists or pain specialists knowledgeable of and skilled in the use of Schedule II
 8 opioids to treat cancer pain, as approved by the FDA.
 9

10 193. In its September 29, 2008 press release regarding the FCA suit against
 11 Cephalon, the DOJ stated that Cephalon's focus on physicians other than oncologists
 12 constituted off-label marketing.
 13

14 194. On February 21, 2013, IRC Prior Authorization Assistant Tamara
 15 Kalmykova ("Kalmykova") emailed Guzman regarding one of Dr. Banchik's
 16 patients, stating that the approval request was denied partly because Medicaid
 17 identified Dr. Banchik as a neurologist and required proof that Dr. Banchik
 18 specialized in pain management.
 19

20 195. Dr. Banchik is neurologist at the Neurology Centers of Palm Beach, as
 21 stated on her patient forms and on her biography on the Neurology Center's website.
 22

23 196. The Neurology Centers of Palm Beach's website indicates that Dr.
 24 Banchik has experience with and provides lectures on pain management, but that her
 25 primary background is in neurology, which includes the specialty area of headaches.
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 197. The Neurology Center of Palm Beach's website does not list cancer
2 treatment as a specialty area, although it does list headaches/migraines and various
3 forms of injuries as areas of focus for the Neurology Center's physicians.
4

5 198. INSYS is targeting doctors who are not oncologists or pain management
6 physicians specializing in cancer treatment and who likely see far more neurological
7 patients than cancer patients.
8

9 199. The FDA contraindicated SUBSYS for acute pain stemming from
10 migraines or headaches, due to the serious consequences that could result from
11 prescribing SUBSYS to patient not on a chronic regiment of opioids for cancer
12 treatment.
13
14

15 200. Dr. Banchik mentioned to Guzman in August 2012 that doctors who
16 were unable to prescribe SUBSYS could refer their patients to her to write the
17 prescription, which indicates that Dr. Banchik was likely unfamiliar with these
18 referred patients' particular histories, which thus increases the chances of SUBSYS
19 causing serious side effects in these new patients who doctors unfamiliar with
20 SUBSYS referred specifically for such a prescription.
21
22

23 201. INSYS's pursuit of relationships with non-FDA approved doctors is not
24 an uncommon practice for the company.
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 202. On or around August 16, 2012, National Trainer Hill admitted in a text
2 message to Guzman that none of the attendees at a speaker program she had recently
3 conducted were oncologists or pain specialists.
4

5 203. Hill serves as the INSYS National Trainer and was a former Cephalon
6 employee, who should be aware of FDA standards.
7

8 204. On or around April 19, 2013 during the Arizona conference, a South
9 East Region sales representative stated that she had a neurologist that was prescribing
10 1600 mcg for a patient.
11

12 **INSYS's Off-Label Marketing Results in Doctors Prescribing SUBSYS for**
13 **Contraindications, Off-Label Use, and Over-Titrating.**
14

15 205. INSYS's off-label marketing schemes have resulted in doctors writing
16 prescriptions for contraindicated uses, such as postoperative pain, and for off-label
17 uses, such as back pain.
18

19 206. INSYS has also crafted the "kiss of death" and "effective dosage"
20 messages, which encourage doctors to start patients at a higher dose than 100 mcg
21 and/or titrate patients quickly, which is counter to the FDA dosage instructions and
22 can be very dangerous with such a potent opioid agonist.
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

Prescriptions for Contraindications.

207. SUBSYS is contraindicated for postoperative pain and for headaches/migraines because life-threatening respiratory depression and death could occur in patients.

208. INSYS ignores the FDA contraindications warnings and encourages doctors to recommend SUBSYS for such uses, which has resulted in prescriptions for contraindicated conditions.

209. On or around February 21, 2013, Kalmykova emailed Guzman regarding one of Dr. Banchik's Medicaid patients, stating that his approval request had been denied because the office notes focused on the patient's knee surgery rather than the cancer diagnosis, under which the request was filed.

210. Dr. Banchik's Medicaid patient whom Kalmykova emailed Guzman about on or around February 21, 2013 had previously had cancer but the SUBSYS prescription was to treat the patient's post-operation pain following knee surgery.

211. Kalmykova also indicated in her email to Guzman on or around February 21, 2012 that the IRC needed office notes that supported the correct diagnosis (cancer), thus impliedly asking Guzman and Dr. Banchik to alter office notes that had stated the actual purpose for the Medicaid patient's prescription (post-operative pain) so the request would fit CMS's approval requirements.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 212. On or around March 18, 2013, Kalmykova followed up with Guzman
2 regarding Dr. Banchik's Medicaid patient, asking Guzman if INSYS now had all the
3 required documentation from Dr. Banchik, especially because "the patient has
4 actually tried the medication due to the one time approval that we got from his work
5 comp back in February."

6
7
8 213. The February 2012 prior authorization for SUBSYS Dr. Banchik's
9 Medicaid patient received through worker's compensation was not for treatment of
10 the patient's cancer pain, but rather for his knee injury.

11
12 214. The Relator believes that the initial prescription for Dr. Banchik's
13 Medicaid patient in February 2012 was 200 mcg, 30 units.
14

15 215. According to an email from Burlakoff on May 13, 2012, 30 units of
16 SUBSYS at a 200 mcg dose costs about \$900 dollars and 120 units at a 400 mcg dose
17 costs approximately \$5,100.
18

19 **Prescriptions for Off-Label Uses.**

20
21 216. The treatment of back pain is one of the primary off-label uses for which
22 doctors prescribe SUBSYS.

23 217. On or around April 18, 2013 during the Arizona INSYS conference,
24 management and sales representatives discussed a method for encouraging doctors to
25 prescribe SUBSYS for the off-label use of treating back pain: instruct the physician
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 to ask the patient if there was anything they could not do during the day because of
2 their back.

3
4 218. During this conference meeting on or around April 18, 2013, Hill and
5 Tondre stated representatives could rephrase this by asking if the patient was
6 restricted from doing anything because of pain or asking about the patient's
7 "functionality."
8

9
10 219. After Tondre provided an alternative method for promoting SUBSYS for
11 the off-label use of back pain, Rowan stated that INSYS was lucky to have Tondre's
12 knowledge and then instructed the representatives to paint a picture and allow the
13 doctor "to go there themselves."
14

15 220. INSYS's instructions to representatives on how they can sell SUBSYS
16 for non-FDA approved uses without "sounding off-label" and marketing SUBSYS by
17 utilizing the mantra "pain is pain" has resulted in a substantial number of off-label
18 prescriptions, many for Medicare and Medicaid patients.
19

20
21 221. In order to enroll in the REMS program and be authorized by the FDA
22 to prescribe SUBSYS, physicians must sign a TIRF form stating that he or she
23 understands the SUBSYS indication.
24

25 222. On or around March 6, 2013, Dr. Gatz prescribed SUBSYS for a
26 Medicare patient using diagnosis codes 724.2 (lumbago), 722.52, and 721.3 for
27
28

1 “lumbosacral spondylosis” and “lumbar radiculopathy,” which are, respectively, a
 2 degenerative condition affecting the lower spine and lower-back nerve root pain.

3
 4 223. On or around March 11, 2013, Dr. Gatz prescribed 600 mcg of SUBSYS
 5 for a Medicare patient with chronic pain; a staff member in Dr. Gatz’s office
 6 confirmed in a March 18, 2013 text message to Guzman that the patient had chronic
 7 pain and not cancer.
 8

9 224. On or around April 11, 2013, Doctor Daniel Ettegui (“Dr. Ettegui”)
 10 prescribed 800 mcg of SUBSYS for a Medicare patient with the diagnosis codes of
 11 “Amputation of Leg Above Knee 897.2; Lumbosacral Plexus Lesions 353.1; Sciatica
 12 Neuralgia 724.3; Lumber Radiculopathy 724.4.”
 13
 14

15 225. On or around April 12, 2013 INSYS Director of Managed Markets Mike
 16 Grury (“Grury”) sent Burlakoff and Guzman text messages stating that Jessica
 17 Chavez from the IRC contacted Medicare in order to get the patient approved for a
 18 voucher, which INSYS can use to sway the patient’s purchasing decision and
 19 potentially dissuade them from less expensive alternatives and generic medications.
 20
 21

22 226. On December 18, 2012, in text messages between Jay Patel (“Patel”)
 23 from Apex Pharmacy and Guzman, Patel confirmed that the diagnosis provided by
 24 Dr. Gatz for a SUBSYS prescription was for patient Joseph Leo’s back pain.
 25

26 227. On February 11, 2013, a staff member from Dr. Gatz’s office sent
 27 Guzman a text message stating that they had just found out that patient Joseph Leo
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 had cancer, verifying that Dr. Gatz had previously prescribed SUBSYS for the off-
 2 label use of treating his back pain.

3 **Falsification of Documents to CMS.**

4
 5 228. The IRC used Dr. Gatz's new cancer diagnosis for Joseph Leo to
 6 continue obtaining approval for the patient's SUBSYS prescription to treat his back
 7 pain, particularly because the IRC stated at the April 2013 conference that the
 8 department reviews patients' medical information to find cancer to obtain prior
 9 authorization.
 10

11
 12 229. The Relator possess knowledge of at least one instance in which the IRC
 13 utilized a previous cancer diagnosis or a cancer diagnosis found after the patient
 14 already received SUBSYS to treat a non-cancer condition in order to gain prior
 15 authorization from CMS for the non-cancer use through falsification of documents.
 16

17
 18 230. In or around late April or early May 2013, the IRC filled out a prior
 19 authorization form and identified the diagnosis as cancer; however, upon receiving
 20 the form, Dr. Gatz's office whited out the cancer diagnosis and wrote "chronic pain,"
 21 as this was the reason Dr. Gatz had prescribed SUBSYS.
 22

23
 24 231. In or around late April or early May 2013, after Dr. Gatz modified the
 25 prior authorization to reflect "chronic pain" as the diagnosis, the IRC indicated to
 26 CMS that the form was incorrect and sent a "corrected" form, with the cancer
 27 diagnosis, to CMS.
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

232. While Dr. Gatz did not participate in the falsification of the prior authorization form sent to CMS in or around April or May 2013, he and the IRC have worked together in other cases to submit false information to CMS.

233. On or around December 18, 2012, Dr. Gatz filled out an IRC prior authorization form for a patient and identified the diagnosis as “neoplastic pain,” which matches code 338.3 (Breakthrough Cancer Pain) that the IRC included in the Medicare form for the same patient on or around December 21, 2012.

234. Dr. Gatz’s January 23, 2013 Patient Face Sheet (which provides background information on the client) for the patient with the December 2012 neoplastic pain diagnosis, uses diagnosis codes 719.48 (pain in joint) and 337.00 (nerve damage).

235. The difference in the diagnosis codes used on the forms submitted to CMS by the IRC and Dr. Gatz with the Patient Face Sheet indicates that Dr. Gatz was prescribing SUBSYS for nerve and joint pain, but he and the IRC were using the cancer diagnosis to obtain CMS approval.

Switching Patients from Actiq Indicates the Large Number of Medicare and Medicaid Patients being Prescribed SUBSYS.

236. One of INSYS’s primary marketing plans is to encourage doctors to switch patients from Actiq and Fentora to SUBSYS.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 237. During a conference call on or around December 12, 2012, Guzman sent
2 a text message to Hill stating that most patients using Actiq are on Medicare or
3 Medicaid, in response to management instructing the sales representatives on the call
4 to switch Actiq patients to SUBSYS while also stating that compliance issues existed
5 when offering Medicare and Medicaid patients SUBSYS.
6
7

8 238. INSYS has been successful in inducing doctors to switch patients from
9 Actiq to SUBSYS, including Dr. Liporace, Dr. Krost, Dr. Banchik, and Dr. Gatz in
10 Guzman's territory alone.
11

12 239. On or around February 11, 2013, Dr. Gatz prescribed 100 mcg of
13 SUBSYS for a Medicare patient.
14

15 240. On or around March 19, 2013, Dr. Banchik prescribed SUBSYS for a
16 Medicaid cancer patient.
17

18 241. Guzman is informed and based thereon alleges that Medicare and
19 Medicaid patients account for a substantial amount of SUBSYS purchasers in her
20 territory and all over the country.
21

22 242. INSYS management, such as Burlakoff, are careful to officially state
23 that vouchers and other incentives cannot be given to Medicare or Medicaid patients
24 for compliance reasons but management encourages and/or is aware that vouchers
25 and incentives are provided to persuade Medicare and Medicaid to purchase
26 SUBSYS.
27
28

1 243. On December 12, 2012, a concerned Guzman sent Burlakoff a text
2 message stating that Dr. Banchik had “put a bunch [of] Medicare patients” on free
3 SUBSYS product, to which Burlakoff responded that he spoke with Babich and that
4 it was fine.
5

6
7 **Titration and Over-Prescribing.**

8 244. INSYS disregards the FDA’s titration warning and encourages doctors
9 to prescribe strong doses of SUBSYS.
10

11 245. The FDA states on the SUBSYS label that the initial dose to treat
12 episodes of breakthrough cancer pain is always 100 mcg.
13

14 246. The SUBSYS label instructs doctors to prescribe the initial titration
15 supply of 100 mcg SUBSYS units, which limits the number of units in the home
16 during titration, and to avoid prescribing a higher dose until patients have used up all
17 units to prevent confusion and possible overdose.
18

19 247. The FDA states that patients should take a maximum of two doses of
20 SUBSYS for any breakthrough pain episode.
21

22 248. In or around August 2012, INSYS created a new marketing tactic
23 referred to as the “effective dosage” or “the kiss of death” message.
24

25 249. The effective dosage message and the kiss of death consists of telling
26 doctors that 100 mcg is not effective for pain relief and continually pushing them to
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 titrate to higher dosages, with the “magic number” referred to in the April 2013
2 Arizona conference as 800 mcg.

3
4 250. As part of the effective dosage message or kiss of death campaign,
5 INSYS sends a “Daily Rep Report for Low Strength Use” via email every day for
6 dosages at or below 400 mcg to sales representatives.

7
8 251. While INSYS refrains from referencing the kiss of death or the effective
9 dosage message in official emails and statements, INSYS management encourages
10 this marketing scheme in person, over the telephone, and through some text
11 messages.

12
13 252. On or around August 24, 2012, Burlakoff sent a text message to Guzman
14 and other representatives stating, “We will do the Matt
15 Napolitano/Marketing/effective dose message.”

16
17 253. Napolitano is a former Cephalon marketing executive.

18
19 254. On or around September 6, 2012, Burlakoff sent a text message to
20 Guzman and other sales professionals stating that INSYS would “get together as a
21 whole company, and review ‘effective dose message;’” indicating that this message is
22 used throughout INSYS.

23
24 255. INSYS’s off-label marketing titration campaign has resulted in doctors
25 starting patients on SUBSYS dosages that are higher than the FDA-approved 100
26 mcg.
27
28

1 256. On or around May 13, 2013, Burlakoff sent an email containing a chart
2 of twelve new patients for the week of May 11, all of which were trying SUBSYS for
3 the first time. Only one individual had 100 mcg listed under the "strength" column,
4 with the other eleven patients receiving strengths between 200 mcg and 1600 mcg,
5 with the average dosage level at approximately 600 mcg.
6

7
8 257. On or around March 1, 2013, Guzman received a voicemail from Patel
9 of Apex Pharmacy stating that the 1200 mcg dosage of SUBSYS for a patient was
10 too high, and that if the prior authorization had not been completed, that INSYS
11 should hold off and return the patient to 800 mcg.
12

13
14 258. In or around March 2013, Burlakoff sent an email congratulating one
15 individual who had encouraged a doctor to switch a patient from 1600 mcg of Actiq
16 to a SUBSYS prescription that would be titrated to 1200 mcg, and then stated "Cha
17 Ching again!" for the \$40,320 that INSYS would make from the sale to this patient.
18

19 259. On or around April 12, 2013, Hill told Guzman during a conversation
20 that the 10-pack of SUBSYS was only to discourage a patient from staying on 100
21 mcg and was to force them to go up in strength.
22

23 260. During the conversation on or around April 12, 2013, Hill told Guzman
24 that Linden Care, upon which INSYS is increasingly relying to supply SUBSYS,
25 will only dispense a 10-pack of 100 mcg or 200 mcg and up.
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 261. On or around April 18, 2013, Rowan instructed representatives during
2 the INSYS conference to “increase the strength as much as possible – that will give
3 you the most bang for your buck.”
4

5 262. On or around April 18, 2013, one sales representative stated during a
6 conference meeting that a doctor had prescribed a 1200 mcg and a 600 mcg dose to a
7 patient, with one being covered by insurance and the other being covered out-of-
8 pocket.
9

10 263. On the SUBSYS label, the FDA states that, “To reduce the risk of
11 overdose during titration, patients should have only one strength of SUBSYS
12 available at any time.”
13
14

15 264. After the representative mentioned the dual doses for one patient during
16 the April 2013 conference meeting, Rowan and Gurrieri offered a way around the
17 FDA and CMS standards by stating that one prescription could be filled one day and
18 the second could be filled the next.
19

20 265. On or around April 18, the sales representative stated during the
21 conference meeting that the doctor had switched the patient with two prescriptions
22 doses from another fentanyl product, but prescribed the same amount of mcg for
23 SUBSYS.
24
25

26 266. The SUBSYS label states that, “When prescribing, do not switch
27 patients on a mcg per mcg basis from any other oral transmucosal fentanyl product to
28

1 SUBSYS;" the FDA warns against this under the "Medication Errors" portion of the
 2 label, stating in bold that this can result in a fatal overdose.

3
 4 **COUNT I: FALSE CLAIMS ACT VIOLATIONS**

5 **31 U.S.C. § 3729(a)(1) Against**

6 **Defendants**

7
 8 267. Guzman realleges and incorporates the allegations set forth above as
 9 though fully set forth therein.

10 268. Defendants knowingly caused to be presented to the United States
 11 Government false or fraudulent claims for payment or approval under the federally-
 12 funded Medicaid and Medicare programs in violation of 31 U.S.C. § 3729(a)(1) when
 13 INSYS violated 42 U.S.C. § 1320a-7b with its structured kickback system to induce
 14 doctors to recommend SUBSYS because 42 U.S.C. § 1320a-7b(g) provides that a
 15 claim that includes items or services resulting from a violation of this section
 16 constitutes a false or fraudulent claim for purposes of the federal False Claims Act.
 17
 18
 19

20 269. Defendants knowingly offered kickbacks to doctors when its managers
 21 instructed representatives to offer incentives to doctors in exchange for SUBSYS
 22 prescriptions, even though INSYS management knew this violated FCA laws,
 23 including during the April 2013 conference when Rowan told representatives not to
 24 "put in black and white" that speaker programs and fees are based on the amount of
 25 SUBSYS a doctor prescribes.
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 270. INSYS management and sales representatives shared methods in which
2 to maneuver around anti-kickback standards and compliance laws, such as ordering
3 meals during lunch as to-go orders but instructing the restaurant to credit the
4 representative when they later brought in just the doctor and his or her spouse, or by
5 ordering televisions through caterers for speaker programs.
6
7

8 271. INSYS management was aware of FCA laws and compliance standards
9 but justified its instructions to sales representatives to violate such laws a standards,
10 such as when Regional Sales Manager Rowan stated during the April 2013
11 conference that he did not believe he was doing anything wrong because he was
12 inducing doctors with food, and then stated that he was not asking the sales
13 representatives to do anything wrong, just to be aware of how they can be a top sales
14 person.
15
16
17

18 272. Defendants knowingly caused to be presented to the Government false
19 or fraudulent claims for payment or approval under the federally-funded Medicaid
20 program when in or around February 21, 2013, it submitted to CMS forms indicating
21 that a previous cancer diagnosis was the reason for Dr. Banchik prescribing SUBSYS
22 for a Medicaid patient when the prescription was being used to treat postoperative
23 knee pain, a contraindicated use; this practice is widespread throughout INSYS,
24 particularly because the IRC obtains approval from Medicaid and Medicare for the
25 entire company.
26
27
28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

273. Defendants knowingly caused to be presented to the Government false or fraudulent claims for payment or approval when in late April or early May 2013, the IRC filled out a prior authorization form and identified the diagnosis as cancer on the form but Dr. Gatz later whited out the cancer diagnosis and wrote “chronic pain” (the reason for the SUBSYS prescription); the IRC told CMS that the form was incorrect with the chronic pain diagnosis and sent a “corrected” form. This practice is widespread throughout INSYS, particularly because the IRC obtains approval from Medicaid and Medicare for the entire company.

274. Defendants knowingly caused to be presented to the Government false or fraudulent claims for payment or approval when in or around December 18, 2012, the IRC, working with Dr. Gatz, submitted to CMS prior authorization and Medicare forms indicating that the patient’s diagnosis was neoplastic pain when Dr. Gatz’s Patient Face Sheet noted that the patient had joint and nerve pain, a Sheet to which the IRC had access; this practice is widespread throughout INSYS, particularly because the IRC obtains approval from Medicaid and Medicare for the entire company.

275. Defendants knowingly caused to be presented to the Government false or fraudulent claims for payment or approval when it engaged in off-label marketing, such as failing to meet the off-label dissemination requirements of 21 U.S.C. §360aaa, distributing misbranded drugs in violation of 21 U.S.C. §331(a), and

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 encouraged doctors to prescribe SUBSYS for uses it knew were not approved by the
 2 FDA and assisted through the IRC in obtaining and approval and payment from
 3 Medicaid and Medicare for SUBSYS prescriptions for non-approved uses in violation
 4 of 42 U.S.C §1396r-8(k)(3) and 42 U.S.C. §§ 1395w-102 – §1395w-104.
 5

6 276. The United States, unaware of the falsity of the claims and/or statements
 7 made by Defendants and in reliance on the accuracy thereof, paid Defendants for
 8 such false or fraudulent claims.
 9

10 277. By reasons of the acts and conduct of Defendants in violation of 31
 11 U.S.C. § 3729(a)(1), the United States has suffered actual damages, including the
 12 total amounts paid in response to all such false or fraudulent claims for payment. In
 13 addition, the United States is entitled to recover civil money penalties, and other
 14 monetary relief as deemed appropriate.
 15

16 **COUNT II: OFF-LABEL DISSEMINATION VIOLATIONS**

17 **21 U.S.C. §360aaa Against Defendants**

18 278. Guzman realleges and incorporates the allegations from Paragraphs 1
 19 through 266, inclusive, as though fully set forth therein
 20

21 279. A manufacturer may disseminate information concerning the safety,
 22 effectiveness, or benefit of a use not described in the approved labeling only if: (1)
 23 there is an application filed pursuant to 21 U.S.C. § 355; (2) the information meets
 24 the requirements of 21 U.S.C. § 360aaa-1; (3) the information is not derived from
 25
 26
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 clinical research conducted by another manufacturer or permission has been given to
 2 use such information; (4) the manufacturer has, within 60 days before dissemination
 3 submitted to the Secretary (A) a copy of the information to be disseminated and (B)
 4 any clinical trial information relating to the safety or effectiveness of the new use; (5)
 5 the manufacturer has complied with section 360aaa-3; (6) along with the information
 6 on the new use to be disseminated, the manufacturer includes a statement disclosing
 7 (A)(i) that the use is not approved, (ii) that the information is being disseminated at
 8 the manufacturer's expense, (iii) the names of the authors who have received
 9 compensation from the manufacturer, (iv) the official labeling for the drug, (v) a
 10 statement that there are products or treatments that have been approved for the use,
 11 (vi) identification of any person that provided funding for the research, and (B) a
 12 bibliography of other articles that have been published about the use of the drug.

13
 14
 15
 16
 17
 18 280. Defendants did not satisfy these requirements before encouraging
 19 doctors to prescribe SUBSYS for contraindicated and off-label uses, such as for
 20 postoperative pain and back pain, and before it pursued doctor who were neither
 21 oncologist nor pain management specialists knowledgeable in opioids to prescribe
 22 SUBSYS for patients, including those insured by Medicare and Medicaid, and
 23 therefore violated 21 U.S.C. § 360aaa.
 24

25
 26 281. Because Defendants did not meet the 21 U.S.C. § 360aaa dissemination
 27 requirements and thus engaged in off-label marketing of SUBSYS, they violated 31
 28

1 U.S.C. § 3729(a)(1) by knowingly presenting or causing to be presented to the United
 2 States Government false or fraudulent claims for payment or approval under the
 3 federally-funded Medicaid and Medicare programs.
 4

5 **COUNT III: MEDICAID NON-APPROVED USE VIOLATIONS**

6 **42 U.S.C. § 1396r-8(k)(3) Against Defendants**

7
 8 282. Guzman realleges and incorporates the allegations from Paragraphs 1
 9 through 266, inclusive, as though fully set forth therein
 10

11 283. Reimbursement by Medicaid is, with only one rare exception (an
 12 anticancer chemotherapeutic regimen), prohibited if the drug is not being used for a
 13 medically accepted indication. 42 U.S.C. §1396r-8(k)(3).
 14

15 284. 42 U.S.C. §1396r-8 (k)(6) defines a medically accepted indication as one
 16 which is approved under the Food, Drug, and Cosmetic Act.
 17

18 285. The FDA approved SUBSYS for the limited use of treatment for
 19 breakthrough pain in cancer patients.
 20

21 286. INSYS management instructed sales representatives on and allowed
 22 former Cephalon employees to share methods for promoting SUBSYS to doctors for
 23 off-label and contraindicated uses without sounding “off-label,” including at the April
 24 2013 INSYS conference in Arizona and during an early 2013 conference call in
 25 which former Cephalon employee Dan Tondre explained his sales motto “pain is
 26 pain.”
 27
 28

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 287. During the April 2013 INSYS conference in Arizona, Defendants
2 instructed sales representatives on methods for promoting SUBSYS for treating
3 sickle cell anemia and back pain, neither of which were conditions approved or
4 indicated by the FDA for SUBSYS use.
5

6 288. During the April 2013 INSYS conference in Arizona, Manager Joe
7 Rowan told sales representatives, "I don't want to know what you do," but stated that
8 they should do what they need to, but "it's not on me."
9
10

11 289. Defendants are aware that doctors are prescribing SUBSYS for off-label
12 and contraindicated uses for Medicaid patients, which is prohibited by 42 U.S.C.
13 §1396r-8(k)(3), encourages doctors to write and continue writing these prescriptions,
14 and assists them in gaining authorizations for the off-label and contraindicated
15 prescriptions through the IRC.
16
17

18 290. In February 2013, the IRC worked to obtain CMS approval for a
19 Medicaid patient of Dr. Banchik's to treat the pain he experienced following knee
20 surgery by using the patient's past history of cancer.
21

22 291. The FDA contraindicates SUBSYS for the use in treating postoperative
23 pain.
24

25 292. The FDA states that SUBSYS is to be prescribed by oncologist or pain
26 specialists familiar with opioids.
27
28

1 293. Defendants pursued relationships with non-oncologists, such as
2 neurologists, for the purpose of encouraging those doctors to prescribe SUBSYS.

3 294. Medicaid patients account for a significant portion of SUBSYS users.

4 295. Defendants violated 42 U.S.C. § 1396r-8(k)(3) when they encouraged
5 doctors to prescribe SUBSYS for uses they knew were not approved by the FDA and
6 assisted through the IRC in obtaining approval and payment from Medicaid for
7 SUBSYS prescriptions for non-approved uses.

8 296. Because Defendants violated 42 U.S.C. § 1396r-8(k)(3) by encouraging
9 doctors to prescribed SUSYS for non-approved uses and assisted doctors in obtaining
10 approval and payment for non-approved uses, they also violated 31 U.S.C. §
11 3729(a)(1) by knowingly presenting or causing to be presented to the United States
12 Government false or fraudulent claims for payment or approval under the federally-
13 funded Medicaid program.

14 **COUNT IV: MEDICARE NON-APPROVED USE VIOLATIONS**

15 **42 U.S.C. §§ 1395w-102 – §1395w-104 Against Defendants**

16 297. Guzman realleges and incorporates the allegations from Paragraphs 1
17 through 266, inclusive, as though fully set forth therein

18 298. Medicare Part D, 42 U.S.C. §§1395w-102 – §1395w-104, states that a
19 plan sponsor is required to provide coverage of qualified prescription drugs.
20
21
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 299. The definition for a covered Medicare drug is outlined in 1395w-102(e),
2 which includes the term “medically accepted indication.”

3 300. 42 U.S.C. §1396r-8 (k)(6) defines a medically accepted indication as one
4 which is approved under the Food, Drug, and Cosmetic Act.
5

6 301. The FDA approved SUBSYS for the limited use of treatment for
7 breakthrough pain in cancer patients.
8

9 302. INSYS management instructed sales representatives on and allowed
10 former Cephalon employees to share methods for promoting SUBSYS to doctors for
11 off-label and contraindicated uses without sounding “off-label,” including at the April
12 2013 INSYS conference in Arizona and during an early 2013 conference call in
13 which former Cephalon employee Dan Tondre explained his sales motto “pain is
14 pain.”
15
16

17 303. During the April 2013 INSYS conference in Arizona, Defendants
18 instructed sales representatives on methods for promoting SUBSYS for treating
19 sickle cell anemia and back pain, neither of which were conditions approved or
20 indicated by the FDA for SUBSYS use.
21
22

23 304. During the April 2013 INSYS conference in Arizona, Manager Joe
24 Rowan told sales representatives, “I don’t want to know what you do,” but stated that
25 they should do what they need to, but “it’s not on me.”
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 305. Defendants' off-label marketing has resulted in doctors prescribing
2 SUBSYS for off-label uses, such as Dr. Gatz writing SUBSYS prescriptions for
3 Medicare patients to treat their back and chronic pain and Dr. Ettedgui prescribing
4 SUBSYS for a Medicare patient to treat his post-amputation and lower-back pain.
5

6 306. Defendants are aware that doctors are prescribing SUBSYS for off-label
7 and contraindicated for Medicare patients, which is prohibited by 42 U.S.C.
8 §§1395w-102 – §1395w-104, and encourages them to write and continue writing
9 these prescriptions, and assists them in gaining authorizations for these off-label and
10 contraindicated prescriptions through the IRC.
11

12 307. In or around December 18, 2012, the IRC and Dr. Gatz submitted forms
13 to Medicare indicating that the patient's diagnosis was neoplastic pain in order to
14 gain approval for the SUBSYS prescriptions; however, Dr. Gatz's Patient Face Sheet
15 indicated that the patient had joint and nerve pain, which are off-label uses.
16

17 308. The FDA states that SUBSYS is to be prescribed by oncologist or pain
18 specialists familiar with opioids.
19

20 309. Defendants pursued relationships with non-oncologists, such as
21 neurologists, for the purpose of encouraging those doctors to prescribe SUBSYS.
22

23 310. Medicare patients account for a significant portion of SUBSYS users.
24

25 311. Defendants violated 42 U.S.C. § 1395w-102 when they encouraged
26 doctors to prescribe SUBSYS for uses it knew were not approved by the FDA and
27
28

1 assisted through the IRC in obtaining approval and payment from Medicare for
 2 SUBSYS prescriptions for non-approved uses.

3
 4 312. Because Defendants violated 42 U.S.C. § 1395w-102 by encouraging
 5 doctors to prescribed SUSYS for non-approved uses and assisted doctors in obtaining
 6 approval and payment for non-approved uses, they also violated 31 U.S.C. §
 7 3729(a)(1) by knowingly presenting or causing to be presented to the United States
 8 Government false or fraudulent claims for payment or approval under the federally-
 9 funded Medicare program.
 10

11
 12 **COUNT V:**
 13 **VIOLATION OF THE CALIFORNIA FALSE CLAIMS ACT**
 14 **(Cal. Gov't. Code § 12651(a)(1))**
 15

16 313. The allegations of paragraphs 1 through 266 are realleged as if fully
 17 set forth herein. The California False Claims Act provides, in pertinent part, that:
 18

19 (a) Any person who commits any of the following acts shall
 20 be liable to the state or to the political subdivision for three
 21 times the amount of damages which the state or the political
 22 subdivision sustains because of the act of that person. A
 23 person who commits any of the following acts shall also be
 24 liable to the state or to the political subdivision for the costs
 25 of a civil action brought to recover any of those penalties or
 26 damages, and may be liable to the state or political
 27 subdivision for a civil penalty of up to ten thousand dollars
 28 (\$10,000) for each false claim:

(1) Knowingly presents or causes to be presented to
 an officer or employee of the state or of any political

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

subdivision thereof, a false claim for payment or approval.

(2) Knowingly makes, uses, or causes to be made or used a false record or statement to get a false claim paid or approved by the state or by any political subdivision.

(3) Conspires to defraud the state or any political subdivision by getting a false claim allowed or paid by the state or by any political subdivision.

...

(7) Knowingly makes, uses, or causes to be made or used a false record or statement to conceal, avoid, or decrease an obligation to pay or transmit money or property to the state or to any political subdivision.

Cal. Gov't. Code § 12651.

314. By virtue of the conduct alleged herein, Defendants, and each of them knowingly caused to be presented to California false claims for payment or approval, in violation of Cal. Gov't. Code § 12651(a)(1).

315. Additionally, Defendants, and each of them gave or caused to be given 'kickbacks' to physicians and other licensed health care professionals to induce them to prescribe Subsys in violation of state law, including Cal. Welfare & Inst. Code s 14107.2.

316. California paid the false claims because of the conduct of Defendants, and each of them. As a result of these payments and the conduct California has been damaged in an amount to be determined at trial.

1 317. For each violation of the California False Claims Act, California is
2 entitled to recover treble damages from Defendants, and each of them. *See* Cal.
3 Gov't. Code § 12651(a).
4

5 318. In addition, for each violation of the California False Claims Act,
6 California is entitled to recover from Defendants, and each of them costs of this
7 action, as well as a civil penalty of up to \$10,000.00 per false claim. *Id.*
8

9
10 **COUNT VI**
11 **VIOLATION OF THE CALIFORNIA FALSE CLAIMS ACT**
12 **(Cal. Gov't. Code § 12651(a)(2))**

13 319. The allegations of paragraphs 1 through 266 are realleged as if fully
14 set forth herein. By virtue of the conduct alleged herein, Defendants, and each of
15 them knowingly made or used, or knowingly caused to be made or used, false records
16 or statements to get false claims paid or approved by California, in violation of Cal.
17 Gov't. Code § 12651(a)(2).
18

19 320. California paid the false claims because of the conduct of Defendants,
20 and each of them. As a result of these payments and the illegal conduct California
21 has been damaged in an amount to be determined at trial.
22

23 321. For each violation of the California False Claims Act, California is
24 entitled to recover treble damages from Defendants, and each of them. *See* Cal.
25 Gov't. Code § 12651(a).
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

327. In addition, for each violation of the California False Claims Act, California is entitled to recover from Defendants, and each of them costs of this action, as well as a civil penalty of up to \$10,000.00 per false claim. *Id.*

328. The allegations of paragraphs 1 through 266 are realleged as if fully set forth herein.

330. California paid the false claims because of the conduct of Defendants, and each of them.

332. For each violation of the California False Claims Act, California is entitled to recover treble damages from Defendants, and each of them. See Cal. Gov't. Code § 12651(a).

334. **WHEREFORE**, Relator respectfully requests this Court to enter judgment for California and against Defendants, and each of them on each of Counts VI through IX of this Complaint, and impose damages and penalties in an amount equal to three times the loss sustained by the California Medicaid Program (“Medi-Cal”), plus penalties of \$10,000 for each false claim or statement.

335. The allegations of paragraphs 1 through 266 are re-alleged as if fully set forth herein.

(a) Any person who (1) knowingly presents, or causes to be presented, directly or indirectly, to an officer or employee of the Government a false or fraudulent claim for payment or approval; (2) knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the Government; (3) conspires to defraud the Government by getting a false or fraudulent claim allowed or paid; . . . or (7) knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid, or decrease an obligation to pay or transmit money or property to the Government, shall be liable to the Government for a civil penalty of not less

1 than \$5,500 and not more than \$11,000 for each act
 2 constituting a violation of this section, plus 3 times the
 3 amount of actual damages which the Government sustains
 because of the act of that person. . . .

4 Del. C. § 1201-1202

5
 6 336. Defendants, and each of them knowingly (1) knowingly caused false
 7 claims to be presented for payment; (2) knowingly caused false statements or records
 8 to be used to get false or fraudulent claims paid by the Medicaid program; (3)
 9 conspired to defraud the Government by getting a false or fraudulent claim paid;
 10 and/or (4) knowingly caused to be made or used false records or statements to avoid
 11 or reduce the obligation to repay claims to the Delaware Medicaid Program. Since
 12 this program is jointly funded by Delaware and the United States, Defendants, and
 13 each of them, engaged in conduct which conduct directly resulted in significant
 14 financial loss to the State of Delaware and the United States.
 15

16
 17 337. Additionally, Defendants, and each of them gave or caused to be given
 18 ‘kickbacks’ to physicians and other licensed health professionals to induce them to
 19 prescribe Subsys, in violation of state law, including 31 Del. C. § 1001 *et seq.*
 20

21
 22 338. For each violation of the DFCA, Delaware is entitled to recover treble
 23 damages from Defendants, and each of them and a civil penalty of not less than
 24 \$5,500 and not more than \$11,000 for each violation. 6 Del. C. 1201.
 25

26
 27 339. **WHEREFORE**, Relator respectfully requests this Court to enter
 28 judgment for the State of Delaware and against Defendants, and each of them and

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 impose damages and penalties as follows: an amount equal to three times the loss
 2 sustained by the Medicaid Program, plus penalties of \$11,000 for each violation.

3
 4 **COUNT X**

5 **DISTRICT of COLUMBIA FALSE CLAIMS ACT**

6 **(D.C. OFFICIAL CODE §§ 2-308.13 et seq.)**

7
 8 340. The allegations of paragraphs 1 through 266 are realleged as if full set
 9 forth herein.

10 The DCFCA provides, in pertinent part, that:

- 11
 12 (a) Any person who commits any of the following acts shall
 13 be liable to the District for 3 times the amount of
 14 damages which the District sustains because of the act
 15 of that person. A person who commits any of the
 16 following acts shall also be liable for the costs of a civil
 17 action brought to recover penalties or damages, and may
 18 be liable to the District for a civil penalty of not less
 19 than \$5,000, and not more than \$10,000 for each false
 20 claim for which the person (1) knowingly presents, or
 21 causes to be presented, to an officer or employee of the
 22 District a false claim for payment or approval; (2)
 23 knowingly makes, uses, or causes to be made or used, a
 24 false record or statement to get a false or fraudulent
 25 claim paid or approved by the District; (3) Conspires to
 26 defraud the District by getting a false claim allowed or
 27 paid by the District; . . . or (7) Knowingly makes or
 28 uses, or causes to be made or used, a false record or
 statement to conceal, avoid, or decrease an obligation to
 pay or transmit money or property to the Government,
 shall be liable to the District.

27 D. C. Code § 2.308-14(a).

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 341. Defendants, and each of them knowingly (1) knowingly caused false
2 claims to be presented for payment; (2) knowingly caused false statements or records
3 to be used to get false or fraudulent claims paid by the Medicaid program; (3)
4 conspired to defraud the District by getting a false or fraudulent claim paid; and/or
5 (4) knowingly caused to be made or used false records or statements to avoid or
6 reduce the obligation to repay claims to the District's Medicaid Program. Since this
7 program is jointly funded by the District and the United States, Defendants, and each
8 of them, engaged in conduct which directly resulted in significant financial
9 loss to the District of Columbia and the United States.
10

11 342. Additionally, Defendants, and each of them gave or caused to be given
12 'kickbacks' to physicians and hospitals to induce the physicians to purchase and/or
13 prescribe Defendants, and each of them drugs, in violation of state law, including
14 D.C. Code § 3-702
15

16 343. **WHEREFORE**, Relator respectfully requests this Court to enter
17 judgment for the District of Columbia and against Defendants, and each of them on
18 each of the Counts of this Complaint, and impose damages and penalties in an
19 amount equal to three times the loss sustained by the District of Columbia Medicaid
20 program, plus penalties of \$10,000 for each false claim or statement.
21
22
23
24
25
26
27
28

COUNT XI
VIOLATION OF THE FLORIDA FALSE CLAIMS ACT
§§ 68.081-.092, FLORIDA STATUTES

344. The allegations of paragraphs 1 through 266 are realleged as if fully set forth herein.

Fla. Stat. 68.082(2) provides liability for any person who (a) knowingly presents, or causes to be presented, to an officer or employee of an agency a false or fraudulent claim for payment or approval; (b) knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by an agency; (c) conspires to submit a false or fraudulent claim to an agency or to deceive an agency for the purpose of getting a false or fraudulent claim allowed or paid...is liable to the state for a civil penalty of not less than \$5,500 and not more than \$11,000 and for treble the amount of damages the agency sustains because of the act or omission of that person.

345. Defendants, and each of them knowingly made, used, or caused to be made or used, false records or statements to conceal, avoid, or decrease an obligation to pay or transmit money to the State of Florida.

346. Defendants, and each of them knowingly presented or caused to be presented false claims for payment to the Florida Medicaid Program creating liability for a false claims action pursuant to §68.081, Fla. Stat., et. seq.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 347. As a result of the conduct of Defendants, and each of them, set forth in
2 this count, the State of Florida paid the improper Medicaid claims and has suffered
3 actual damages.
4

5 348. Additionally, Defendants, and each of them gave or caused to be given
6 'kickbacks' to physicians and other licensed health professionals to induce them to
7 prescribe Subsys in violation of state law, including Fla. Stat. §§ 409.920.
8

9 349. Pursuant to §§ 68.082(2) and 68.086, Fla. Stat., the Defendants, and
10 each of them, are liable for treble the actual damages sustained, not less than \$5,500
11 and not more than \$11,000 penalty per claim, all other relief set forth in said statutes,
12 prejudgment interest, attorneys' fees and court costs.
13
14

15 350. **WHEREFORE**, Relator respectfully requests that judgment be entered
16 in favor of the State of Florida against Defendants, and each of them, as follows:
17

18 351. For treble the amount of the State of Florida's actual damages plus civil
19 penalties of \$11,000.00 for each false claim submitted; for reasonable attorney's fees
20 and costs of this civil action; and for such other and further relief as the Court deems
21 just and equitable.
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XII
VIOLATION OF THE GEORGIA FALSE MEDICAID CLAIMS ACT
(GEORGIA CODE 49-4-168 et seq.)

352. The allegations of paragraphs 1 through 266 are realleged as if fully set forth herein. This is a claim for treble damages and civil penalties under the Georgia State False Medicaid Claims Act.

353. Section 49-4-168.1.(a) of the Georgia State False Medicaid Claims Act provides in pertinent part as follows:

Any person who:

(1) Knowingly presents or causes to be presented to the Georgia Medicaid program a false or fraudulent claim for payment or approval;

(2) Knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the Georgia Medicaid program;

(3) Conspires to defraud the Georgia Medicaid program by getting a false or fraudulent claim allowed or paid;

...
 (7) Knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid, or decrease an obligation to pay, repay or transmit money or property to the State of Georgia,

shall be liable to the State of Georgia for a civil penalty of not less than \$5,500.00 and not more than \$11,000.00 for each false or fraudulent claim, plus three times the amount of damages which the Georgia Medicaid program sustains because of the act of such person.

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

1 Defendants, and each of them violated the provisions set forth hereinabove.

2 354. For each violation of the statute, the Commonwealth of Georgia is
3
4 entitled to recover treble damages from Defendants, and each of them. See §49-4-
5 168.1.(a) of the Georgia State False Medicaid Claims Act.

6 355. **WHEREFORE**, the Relator respectfully requests this Court to enter
7
8 judgment for the Commonwealth of Georgia and against Defendants, and each of
9
10 them for an amount of three times the amount of damages sustained by the
11 Commonwealth of Georgia and a civil penalty of \$10,000 for each act of submitting
12 false statements by INSYS, Kapoor, Babich, and Burlakoff.

13
14 **COUNT XIII**

15 **HAWAII FALSE CLAIMS ACT,**

16 **Haw. Rev. Stat. § 661-21, et seq.**

17 356. The allegations of paragraphs 1 through 266 are realleged as if fully set
18
19 forth herein. This is a claim for treble damages and civil penalties under the Hawaii
20 False Claims Act. Haw. Rev. Stat. § 661-21, et seq.

21 357. Defendants, and each of them knowingly presented or caused to be
22
23 presented to an officer or employee of the state a false or fraudulent claim for
24
25 payment or approval.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 358. Defendants, and each of them knowingly made, used, or caused to be
2 made or used, a false record or statement to get a false or fraudulent claim paid or
3 approved by the state.
4

5 359. Defendants, and each of them conspired to defraud the state by getting a
6 false or fraudulent claim allowed or paid.
7

8 360. The Hawaii Medicaid Program, unaware of the falsity or fraudulent
9 nature of the claims caused by Defendants, and each of them, paid for claims that
10 otherwise would not have been allowed.
11

12 361. By reason of these payments, the Hawaii Medicaid Program has been
13 damaged in a substantial amount.
14

15 362. **WHEREFORE**, the Relator respectfully requests this Court to enter
16 judgment for the State of Hawaii and against defendants Defendants, and each of
17 them for an amount of three times the amount of damages sustained by the State of
18 Hawaii and a civil penalty of \$11,000 for each act of submitting false statements.
19
20

21 **COUNT XIV**

22 **ILLINOIS WHISTLE BLOWER REWARD AND PROTECTION ACT**

23
24 363. The allegations of paragraphs 1 through 266 are realleged as if fully set
25 forth herein.
26

27 364. Section 3 of the Illinois WHISTLE BLOWER Reward and Protection
28 Act, 740 ILCS § 175/3, provides in pertinent part:

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

(a) Any person who: ... (7) knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid or decrease an obligation to pay or transmit money or property to the State;... is liable to the State for a civil penalty of not less than \$5,500 and not more than \$11,000, plus 3 times the amount of damages which the State sustains because of the act of that person. A person violating this subsection (a) shall also be liable to the State for the costs of a civil action brought to recover any such penalty or damages

(b) Knowing and knowingly defined. As used in this Section, the terms "knowing" and "knowingly" mean that a person, with respect to information: (1) has actual knowledge of the information; (2) acts in deliberate ignorance of the truth or falsity of the information; or (3) acts in reckless disregard of the truth or falsity of the information, and no proof of specific intent to defraud is required.

365. Defendants, and each of them knowingly made, or used or caused to be made or used, false records or statements, submitted or caused the submission of false claims, and also did these things to conceal, avoid, or decrease an obligation to pay or transmit money or property to the State of Illinois Medicaid Program. Said program is jointly funded by the United States and the State of Illinois. By engaging in the conduct outlined above, Defendants, and each of them caused significant financial loss to the United States and the State of Illinois.

366. Additionally, Defendants, and each of them gave or caused to be given 'kickbacks' to physicians and other health care professionals to induce them to prescribe Subsys in violation of state law, including Ill. Stat., Ch. 305, § 5/8A-3.

367. **WHEREFORE**, the Relator respectfully requests this Court to enter judgment for the State of Illinois and against Defendants, and each of them for an amount of three times the amount of damages sustained by the State of Illinois and a civil penalty of \$11,000 for each act of submitting false statements by Defendants, and each of them.

COUNT XV
VIOLATION OF THE INDIANA FALSE CLAIMS ACT
(INDIANA CODE 5-11-5.5)

368. The allegations of paragraphs 1 through 266 are realleged as if fully set forth herein.

369. Pursuant to the Indiana False Claims Act (IC 5-11-5.5(b)):

(b) A person who knowingly or intentionally:

(1) presents a false claim to the state for payment or approval;

(2) makes or uses a false record or statement to obtain payment or approval of a false claim from the state;

is, except as provided in subsection ©, liable to the state for a civil penalty of at least five thousand dollars (\$5,000) and for up to three (3) times the amount of damages sustained by the state. In addition, a person who violates this section is liable to the state for the costs of a civil action brought to recover a penalty or damages.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 370. Defendants, and each of them knowingly presented, or caused to
2 presented, false claims and/or false records or statements regarding Subsys, to get
3 false claims paid.
4

5 371. Additionally, Defendants, and each of them, gave or caused to be given
6 'kickbacks' to physicians and other health professionals to induce them to prescribe
7 Subsys, in violation of state law, including I.C. 12-15-24-2.
8

9 372. Defendants, and each of them knowingly presented or caused to be
10 presented false claims for payment to the Indiana Medicaid Program creating liability
11 for a false claims action pursuant to I.C. 5-11-5.5.
12

13 373. As a result of conduct set forth in this count, the State of Indiana paid
14 the improper Medicaid claims and has suffered actual damages.
15

16 374. Pursuant to I.C. 5-11-5.5(b), a civil penalty of at least five thousand
17 dollars (\$5,000) and up to three (3) times the amount of damages sustained by the
18 state, and for the costs of this civil action.
19

20 375. **WHEREFORE**, Relator respectfully requests that judgment be entered
21 in favor of the State of Indiana against Defendants, and each of them, as follows:
22

23 376. For a civil penalty of at least five thousand dollars (\$5,000) and for up to
24 three (3) times the amount of damages sustained by the state, and for the costs of this
25 civil action.
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XVI
VIOLATION OF THE LOUISIANA MEDICAL ASSISTANCE PROGRAMS
INTEGRITY LAW
(LA. REV. STATE. ANN § 46:439.1 et seq.)

377. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein.

378. Pursuant to §437.2 of the Louisiana Medical Assistance Programs Integrity Law:

“This Part is enacted to combat and prevent fraud and abuse committed by some health care providers participating in the medical assistance programs and by other persons and to negate the adverse effects such activities have on fiscal and programmatic integrity.”

379. Section 438.3 of the Louisiana Medical Assistance Programs Integrity Law provides in pertinent part:

A. No person shall knowingly present or cause to be presented a false or fraudulent claim.

B. No person shall knowingly engage in misrepresentation to obtain, or attempt to obtain, payment from medical assistance programs funds.

C. No person shall conspire to defraud, or attempt to defraud, the medical assistance programs through misrepresentation or by obtaining, or attempting to obtain, payment for a false or fraudulent claim.

1 This Law defines a "false or fraudulent claim" to be:

2 "... a claim which the health care provider or his billing agent
3 submits knowing the claim to be false, fictitious, untrue, or
4 misleading in regard to any material information. "False or
5 fraudulent claim" shall include a claim which is part of a pattern
6 of incorrect submissions in regard to material information or
7 which is otherwise part of a pattern in violation of applicable
federal or state law or rule. (Section 437.3(8))

8 380. Defendants, and each of them knowingly presented, or caused to
9 presented, false claims for payment and/or false records or statements regarding
10 Subsys in order to get claims paid or in order to conceal, avoid, or decrease an
11 obligation to pay or transmit money to the State of Louisiana Medicaid Program.

12 381. Additionally, Defendants, and each of them gave or caused to be given
13 'kickbacks' to physicians and other health professionals to induce them to prescribe
14 Subsys, in violation of state law, including La. Rev. Stat. § 14:70.5.

15 382. Defendants, and each of them knowingly presented or caused to be
16 presented false claims for payment to the Louisiana Medicaid Program creating
17 liability for a false claims action pursuant to the Louisiana Medical Assistance
18 Programs Integrity Law.

19 383. As a result of the conduct of Defendants, and each of them, as set forth
20 in this count, the State of Louisiana paid the improper Medicaid claims and has
21 suffered actual damages.
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 384. Pursuant to Section 438.6 of the Louisiana Medical Assistance Programs
2 Integrity Law:

3
4 (1) Actual damages incurred as a result of a violation
5 of the provisions of this Part shall be recovered only
6 once by the medical assistance programs and shall
not be waived by the court.

7 (2) Except as provided by Paragraph (3) of this
8 Subsection, actual damages shall equal the difference
9 between what the medical assistance programs paid,
10 or would have paid, and the amount that should have
11 been paid had not a violation of this Part occurred
12 plus interest at the maximum rate of legal interest
13 provided by Civil Code Article 2924 from the date
14 the damage occurred to the date of repayment.

15 (3) If the violator is a managed care health care
16 provider or a health care provider under a voucher
17 program, actual damages shall be determined in
18 accordance with the violator's provider agreement.

19 B. Civil fine.

20 (1) Any person who is found to have violated R.S.
21 46:438.2 shall be subject to a civil fine in an amount
22 not to exceed ten thousand dollars per violation, or an
23 amount equal to three times the value of the illegal
24 remuneration, whichever is greater.

25 (2) Except as limited by this Section, any person who
26 is found to have violated R.S. 46:438.3 shall be
27 subject to a civil fine in an amount not to exceed
28 three times the amount of actual damages sustained
by the medical assistance programs as a result of the
violation.

1 C. Civil monetary penalty.

2 (1) In addition to the actual damages provided in
3 Subsection A of this Section and the civil fine
4 imposed pursuant to Subsection B of this Section,
5 one or more of the following civil monetary penalties
6 may be imposed on the violator:

7 (a) Up to ten thousand dollars for each false or
8 fraudulent claim, misrepresentation, illegal
9 remuneration, or other prohibited act as
10 contained in R.S. 46:438.2, R.S. 46:438.3, or
11 R.S. 46:438.4.

12 (b) Payment of interest on the amount of the
13 civil fine imposed pursuant to Subsection B of
14 this Section at the maximum rate of legal
15 interest provided by Civil Code Article 2924
16 from the date the damage occurred to the date
17 of repayment.

18 (2) Prior to the imposition of a civil monetary
19 penalty, the court shall consider if there are
20 extenuating circumstances as provided in R.S.
21 46:438.7.

22 D. Costs, expenses, fees, and attorney fees.

23 (1) Any person who is found to have violated this
24 Subpart shall be liable for all costs, expenses, and
25 fees related to investigations and proceedings
26 associated with the violation, including attorney fees.

27 (2) All awards of costs, expenses, fees, and attorney
28 fees are subject to review by the court using a
reasonable, necessary, and proper standard of review.

...

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 E.

2 (1) If recovery is due from a health care provider
3 under the provisions of Subsections A and B of this
4 Section, such recovery shall constitute civil
5 liquidated damages for breach of the conditions and
6 requirements of participation in the medical
7 assistance programs which are and shall be
8 construed by the courts to be remedial, but not
9 retroactive, in nature.

10 (2) Any award of civil liquidated damages, costs,
11 expenses, and attorneys' fees shall be in addition to
12 criminal penalties and to the civil monetary penalty
13 provided in Subsection C of this Section.

14 385. **WHEREFORE**, Relator respectfully requests that judgment be entered
15 in favor of the State of Louisiana and against Defendants, and each of them, as
16 follows:

17 386. Actual damages plus interest at the maximum rate of legal interest
18 provided by Civil Code Article 2924 from the date the damage occurred to the date of
19 repayment; a civil fine in an amount not to exceed ten thousand dollars per violation,
20 or an amount equal to three times the value of the illegal remuneration, whichever is
21 greater; and/or for violation of R.S. 46:438.3 a civil fine in an amount not to exceed
22 three times the amount of actual damages sustained by the medical assistance
23 programs as a result of the violation; and civil money penalties up to ten thousand
24 dollars for each false or fraudulent claim, misrepresentation, illegal remuneration, or
25 other prohibited act as contained in R.S. 46:438.2, R.S. 46:438.3, or R.S. 46:438.4,
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 and payment of interest on the amount of the civil fine imposed pursuant to
 2 Subsection B of the above-referenced Louisiana law at the maximum rate of legal
 3 interest provided by Civil Code Article 2924 from the date the damage occurred to
 4 the date of repayment; plus all costs, expenses, and fees related to investigations and
 5 proceedings associated with the violation, including attorney fees; and such other and
 6 further relief as this Honorable Court deems fit and proper.
 7
 8

9
 10 **COUNT XVII**
 11 **FOR VIOLATION OF THE MASSACHUSETTS FALSE CLAIMS ACT**
 12 **(M.G.L. c. 12 § 5A, et seq.)**

13 387. The allegations of paragraphs 1 through 266 are realleged as if fully
 14 set forth herein.
 15

16 388. Defendants, and each of them knowingly made, or used or caused to be
 17 made or used, false claims for payment and/or false records or statements regarding
 18 Subsys in order to get false claims paid and/or to decrease an obligation to pay or
 19 transmit money or property to the Massachusetts Medicaid Program. Said program is
 20 jointly funded by the United States and the Commonwealth of Massachusetts. By
 21 engaging in the conduct outlined above, Defendants, and each of them caused
 22 significant financial loss to the United States and the Commonwealth of
 23 Massachusetts.
 24
 25
 26
 27
 28

389. Additionally, Defendants, and each of them gave or caused to be given 'kickbacks' to physicians and other licensed health professionals to induce them to prescribe Subsys in violation of state law, including Mass. Gen. Law 118E § 41.

390. **WHEREFORE**, the Relator respectfully requests this Court to enter judgment for the Commonwealth of Massachusetts and against Defendants, and each of them for an amount of three times the amount of damages sustained by the Commonwealth of Massachusetts and a civil penalty of \$10,000 for each act of submitting false statements by Defendants, and each of them.

COUNT XVIII
VIOLATION OF THE MICHIGAN MEDICAID FALSE CLAIMS ACT

391. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein

392. Section 400.603 of the State of Michigan's Medicaid False Claims Act provides in part:

(1) A person shall not knowingly make or cause to be made a false statement or false representation of a material fact in an application for medicaid benefits.

(2) A person shall not knowingly make or cause to be made a false statement or false representation of a material fact for use in determining rights to a medicaid benefit.

(3) A person, who having knowledge of the occurrence of an event affecting his initial or continued right to receive a medicaid benefit or the initial or continued right of any

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
 888 17th Street, NW, Suite 900
 Washington, D.C. 20006
 Ph: 202.331.2883 • Fax: 202.261.2835

other person on whose behalf he has applied for or is receiving a benefit, shall not conceal or fail to disclose that event with intent to obtain a benefit to which the person or any other person is not entitled or in an amount greater than that to which the person or any other person is entitled.

M.C.L. §400.602(f) provides:

393. Defendants, and each of them knowingly presented, or caused to presented, false claims for payment and/or false records or statements regarding Subsys in order to get false claims paid and/or in order to conceal, avoid, or decrease an obligation to pay or transmit money to the State of Michigan Medicaid Program.

394. Additionally, Defendants, and each of them gave or caused to be given 'kickbacks' to physicians and other health care professionals to induce them to prescribe Subsys, in violation of state law, including § 400.604.

395. Defendants, and each of them knowingly presented or caused to be presented false claims for payment to the Michigan Medicaid Program creating liability for a false claims action pursuant to Michigan's Medicaid False Claims Act.

396. As a result of the conduct set forth in this count, the State of Michigan paid the improper Medicaid claims and has suffered actual damages.

397. Pursuant to M.C.L. §400.612(1):

A person who receives a benefit which the person is not entitled to receive by reason of fraud or making a fraudulent statement or knowingly concealing a material fact shall forfeit and pay to the state a civil penalty equal to the full amount received plus triple the amount of damages suffered by the state as a result of the conduct by the person.

1
2 398. M.C.L. §400.610a also provides for an award against Defendants for
3 reasonable attorneys' fees, costs and expenses.
4

5 399. **WHEREFORE**, Relator respectfully requests that judgment be entered
6 in favor of the State of Michigan and against Defendants as follows:
7

8 400. A civil penalty equal to the full amount received plus triple the amount
9 of damages suffered by the state, plus attorneys' fees, costs and expenses, and any
10 other and further relief that this Honorable Court deems fit and proper.
11

12 **COUNT XIX**
13 **VIOLATION OF THE MINNESOTA FALSE CLAIMS ACT**
14 **Minn. Stats. 15C.01 – .13**
15

16 401. The allegations of paragraphs 1 through 266 are realleged as though
17 fully set forth herein.
18

19 402. Section 15C.02 of the Minnesota False Claims Act provides in part:

20 (a) A person who commits any act described in clauses (1)
21 to (7) is liable to the state . . . for a civil penalty of not less
22 than \$5,500 and not more than \$11,000 per false or
23 fraudulent claim, plus three times the amount of damages
that the state . . . sustains because of the act of that person,,,

24 (1) knowingly presents or causes to be presented, a false or
25 fraudulent claim for payment or approval;

26 (2) knowingly makes or uses, or causes to be made or used, a false
27 record or statement material to a false or fraudulent claim;
28

(3) knowingly conspires to commit a violation of clause (1),
(2), (4), (5), (6), or (7);

...

(7) knowingly makes or uses, or causes to be made or used,
a false record or statement material to an obligation to pay
or transmit money or property to the state . . . or knowingly
conceals or knowingly and improperly avoids or decreases
an obligation to pay money or transmit property to the state
..."

403. Defendants, and each of them knowingly presented, or caused to
presented, false or fraudulent claims for payment or approval; knowingly made or
used or caused the submission or use of false records or statements regarding Subsys
material to these claims; and/or false records or statements in order to conceal, avoid,
or decrease an obligation to pay or transmit money to the State of Minnesota.
Defendants, and each of them, conspired among themselves and with others to do
these things.

404. Additionally, Defendants, and each of them gave or caused to be given
'kickbacks' to physicians and other health care professionals to induce them to
prescribe Subsys, in violation of state law, including Minn.Stat. 69J.23 et. seq.

405. Defendants, and each of them knowingly presented or caused to be
presented false claims for payment to the Minnesota Medicaid Program creating
liability for a false claims action pursuant to Minnesota's False Claims Act.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

406. As a result of the conduct set forth in this count, the State of Minnesota paid the improper Medicaid claims and has otherwise suffered actual damages.

410. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein

1 (a) knowingly presenting or causing to be presented to an
2 officer or employee of the governmental entity a false claim
3 for payment or approval;

4 (b) knowingly making, using, or causing to be made or used
5 a false record or statement to get a false claim paid or
6 approved by the governmental entity;

7 (c) conspiring to defraud the governmental entity by getting
8 a false claim allowed or paid by the governmental entity;

9 ****

10 (g) knowingly making, using, or causing to be made or used
11 a false record or statement to conceal, avoid, or decrease an
12 obligation to pay or transmit money or property to the
13 governmental entity or its contractors; or

14 (h) as a beneficiary of an inadvertent submission of a false
15 claim to the governmental entity, subsequently discovering
16 the falsity of the claim and failing to disclose the false
17 claim to the governmental entity within a reasonable time
18 after discovery of the false claim.

19 412. Defendants, and each of them, knowingly presented, or caused to
20 presented, false claims for payment and/or false records or statements regarding
21 Subsys in order to get false claims paid, and/or to conceal, avoid, or decrease an
22 obligation to pay or transmit money to the State of Montana Medicaid Program.

23 413. Additionally, Defendants, and each of them gave or caused to be given
24 'kickbacks' to physicians and other health professionals to induce them to prescribe
25 Subsys, in violation of state law, including Mon. 45-6-313.

26 414. As a result of the conduct set forth in this count, the State of Montana
27 paid the improper Medicaid claims and has suffered actual damages.
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 415. Section 3 of the Montana False Claims Act provides in pertinent part:

2 (2) In a civil action brought under [section 5 or 6], a court
3 shall assess not less than two times and not more than three
4 times the amount of damages that a governmental entity
5 sustains because of the person's act, along with costs and
6 attorney fees, and may impose a civil penalty of up to
\$10,000 for each act.

7 416. Section 11 of the Montana False Claims Act also provides for an award
8 of attorneys's fees and costs against Defendants.
9

10 417. **WHEREFORE**, Relator respectfully requests that judgment be entered
11 in favor of the State of Montana and against Defendants and each of them as follows:
12

13 418. Three times the amount of damages that a governmental entity sustains
14 because of the Defendants's acts, along with costs and attorney fees, and a civil
15

16 419. penalty of up to \$10,000 for each act, and any other and further relief
17 that this Honorable Court deems fit and proper.
18

19 **COUNT XXI**

20 **VIOLATION OF THE NEVADA FALSE CLAIMS ACT**

21 **(NRS 357.010 et seq.)**

22 420. The allegations of paragraphs 1 through 266, inclusive, are realleged as
23 though fully set forth herein.
24

25 421. Defendants, and each of them knowingly submitted or caused the
26 submission of false claims for payment and/or made, or used or caused to be made or
27 used, false records or statements regarding Subsys in order to get false claims paid
28

1 and/or to conceal, avoid, or decrease an obligation to pay or transmit money to the
2 State of Nevada Medicaid Program.

3 422. Additionally, Defendants, and each of them gave or caused to be given
4 'kickbacks' to physicians and other health professionals to induce them to prescribe
5 Subsys, in violation of state law, including Nev. Rev. Stats. § 422.560.
6

7 423. **WHEREFORE**, Relator respectfully requests this Court to enter
8 judgment for the State of Nevada and against Defendants and each of them, and to
9 award damages to the State of Nevada as authorized by the provisions of NRS
10 357.040.
11

12
13
14 **COUNT XXII**
15 **CLAIMS OF THE STATE OF NEW HAMPSHIRE**
16 **VIOLATION OF THE NEW HAMPSHIRE FALSE CLAIMS ACT**
17 **(NEW HAMPSHIRE CODE §167:61-b)**

18 424. The allegations of paragraphs 1 through 266 are realleged as though fully
19 set forth herein
20

21 425. The New Hampshire False Claims Act (167:61-b) provides in pertinent
22 part:
23

24 I. Any person shall be liable to the state for a civil penalty
25 of not less than \$5,000 and not more than \$10,000, plus 3
26 times the amount of damages that the state sustains because
27 of the act of that person, who:
28

1 (a) Knowingly presents, or causes to be presented, to an
2 officer or employee of the department, a false or fraudulent
3 claim for payment or approval.

4 (b) Knowingly makes, uses, or causes to be made or used, a
5 false record or statement to get a false or fraudulent claim
6 paid or approved by the department.

7 (c) Conspires to defraud the department by getting a false or
8 fraudulent claim allowed or paid.

9 ...

10 (f) Is a beneficiary of an inadvertent submission of a false
11 claim to the department, who subsequently discovers the
12 falsity of the claim, and fails to disclose the false claim to
13 the department within a reasonable time after discovery of
14 the false claim.

15 426. Defendants, and each of them knowingly presented, or caused to
16 presented, false claims for payment and/or false records or statements regarding
17 Subsys in order to get false claims paid and/or to conceal, avoid, or decrease an
18 obligation to pay or transmit money to the State of New Hampshire Medicaid
19 Program.

20 427. Additionally, Defendants, and each of them gave or caused to be given
21 'kickbacks' to physicians and other health care professionals to induce them to
22 prescribe Subsys, in violation of state law, including N.H. Rev. Stat. §§ 167:61-a, I(I)
23 & (j).

24 428. As a result of the conduct set forth in this count, the State of New
25 Hampshire paid the improper Medicaid claims and has suffered actual damages in
26 excess of \$5,000.00.
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 429. Section 167:61-e of the New Hampshire False Claims Act also provides
2 for an award of attorneys fees and costs against Defendants.

3
4 430. **WHEREFORE**, Relator respectfully requests that judgment be entered
5 in favor of the State of New Hampshire and against Defendants, and each of them, as
6 follows:
7

8 431. A civil penalty of \$10,000, plus 3 times the amount of damages that the
9 state of New Hampshire has sustained because of the acts of Defendants, plus
10 attorneys' fees and costs, and any other and further relief that this Honorable Court
11 deems fit and proper.
12
13

14 **COUNT XXIII**
15 **VIOLATION OF THE NEW JERSEY FALSE CLAIMS ACT**
16 **(2A:32C et. seq.)**
17

18 432. The allegations of paragraphs 1 through 266 are realleged as though fully
19 set forth herein
20

21 433. §2A:32C-3 of the New Jersey False Claims Act provides in pertinent
22 part:
23

24 Any person who commits any of the following acts shall be
25 jointly and severally liable to the State for a civil penalty of
26 not less than and not more than the civil penalty allowed
27 under the federal False Claims Act (31 U.S.C. s.3729 et 37
28 seq.), as may be adjusted in accordance with the inflation
adjustment procedures prescribed in the Federal Civil
Penalties Inflation Adjustment Act of 1990, Pub.L.101-410,

1 for each false claim, plus three times the amount of
2 damages which the State sustains because of the act of that
3 person:

4 a. Knowingly presents or causes to be
5 presented to an employee, officer or agent of
6 the State, or to any contractor, grantee, or other
7 recipient of State funds, a false claim for
8 payment or approval;

9 b. Knowingly makes, uses, or causes to be
10 made or used a false record or statement to get
11 a false claim paid or approved by the State;

12 c. Conspires to defraud the State by getting a
13 false claim allowed or paid by the State;

14 . . .

15 g. Knowingly makes, uses, or causes to be
16 made or used a false record or statement to
17 conceal, avoid, or decrease an obligation to
18 pay or transmit money or property to the State.

19 434. Defendants, and each of them knowingly presented, or caused to
20 presented, false or fraudulent claims for payment and/or false records or statements
21 regarding Subsys in order to get false or fraudulent claims paid; and/or to conceal,
22 avoid, or decrease an obligation to pay or transmit money to the State of New Jersey
23 Medicaid Program.

24 435. Additionally, Defendants, and each of them gave or caused to be give
25 'kickbacks' to physicians and other health professionals to induce them to prescribe
26 Subsys, in violation of state law, including N.J. Stat. §§ 30:4D-17©.
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 436. Defendants, and each of them knowingly presented or caused to be
2 presented false claims for payment to the New Jersey Medicaid Program creating
3 liability for a false claims action pursuant to New Jersey's False Claims Act.
4

5 437. As a result of the conduct set forth in this count, the State of New Jersey
6 paid the improper Medicaid claims and has suffered actual damages.
7

8 438. Pursuant to Section 8 of the New Jersey False Claims Act, the court may
9 also award reasonable attorneys' fees, costs and expenses against the Defendants.
10

11 439. **WHEREFORE**, Relator respectfully requests that judgment be entered
12 in favor of the State of New Jersey and against Defendants, and each of them, as
13 follows:
14

15 440. A civil penalty of not less than and not more than the civil penalty
16 allowed under the federal False Claims Act (31 U.S.C. s.3729 et seq.), as may be
17 adjusted in accordance with the inflation adjustment procedures prescribed in the
18 Federal Civil Penalties Inflation Adjustment Act of 1990, Pub.L.101-410, for each
19 false claim, plus three times the amount of damages, plus attorneys fees, costs and
20 expenses, and any and all other relief that this court deems fit and proper.
21
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XXIV
VIOLATION OF THE NEW MEXICO MEDICAID FALSE CLAIMS ACT
and the NEW MEXICO FRAUD AGAINST TAXPAYERS ACT”

441. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein.

442. §27-14-4 of The New Mexico Fraud Against Taxpayers Act provides in pertinent part that:

“[A] person commits an unlawful act and shall be liable to the state for three times the amount of damages that the state sustains as a result of the act if the person: (A) presents or causes to be presented to the state a claim for payment under the medicaid program knowing that such claim is false or fraudulent; . . . (C) makes, uses, or causes to be made or used a record or statement to obtain a false or fraudulent claim under the medicaid program paid for or approved by the state knowing such record or statement is false; (D) conspires to defraud the state by getting a claim allowed or paid under the medicaid program knowing that such claim is false or fraudulent; (E) makes, uses, or causes to be made or used a record or statement to conceal, avoid, or decrease an obligation to pay or transmit money or property to the state, relative to the medicaid program, knowing that such record or statement is false . . .”

443. Defendants, and each of them knowingly presented, or caused to presented, false or fraudulent claims for payment and/or false records or statements to get claims paid; and or to conceal, avoid, or decrease an obligation to pay or transmit money to the State of New Mexico Medicaid Program.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 444. Additionally, Defendants, and each of them gave or caused to be given
2 'kickbacks' to physicians and other health care professionals to induce them to
3 prescribe Subsys, in violation of state law, including N.M. Stat. § 30-44-1-8.
4

5 445. Defendants, and each of them knowingly presented or caused to be
6 presented false claims for payment to the New Mexico Medicaid Program creating
7 liability for a false claims action pursuant to New Mexico's Fraud Against Taxpayers
8 Act.
9

10 446. As a result the conduct set forth in this count, the State of New Mexico
11 paid the improper Medicaid claims and has suffered actual damages.
12

13 447. §44-9-3 of the New Mexico Fraud Against Taxpayers Act provides in
14 pertinent part that:
15

16 C. A person who violates Subsection A of this section shall be
17 liable for:

18 (1) three times the amount of damages sustained by a
19 state agency because of the violation;

20 (2) a civil penalty of not less than five thousand
21 dollars (\$5,000) and not more than ten thousand
22 dollars (\$10,000) for each violation;

23 (3) the costs of a civil action brought to recover
24 damages or penalties; and

25 (4) reasonable attorney fees, including fees for state
26 agency counsel.
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 (b) knowingly makes, uses, or causes to be made or
2 used, a false record or statement to get a false or
3 fraudulent claim paid or approved by the state or a
4 local government;

5 (c) conspires to defraud the state or a local
6 government by getting a false or fraudulent claim
7 allowed or paid;

8 ...

9 (g) knowingly makes, uses, or causes to be made or
10 used, a false record or statement to conceal, avoid,
11 or decrease an obligation to pay or transmit money or
12 property to the state or a local government; shall be
13 liable: (I) to the state for a civil penalty of not less
14 than six thousand dollars and not more than twelve
15 thousand dollars, plus three times the amount of
16 damages which the state sustains because of the act
17 of that person; and (ii) to any local government for
18 three times the amount of damages sustained by such
19 local government because of the act of that person.

20 452. Pursuant Section 188(3) of the New York False Claims Act, proof of
21 specific intent to defraud is not required.

22 453. Defendants, and each of them knowingly presented, or caused to
23 presented, false or fraudulent claims for payment or approval; false records or
24 statements to get a false or fraudulent claim paid; and/or to conceal, avoid, or
25 decrease an obligation to pay or transmit money to the State of New York Medicaid
26 Program.

27
28
The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 454. Additionally, Defendants, and each of them gave or caused to be given
2 'kickbacks' to physicians and other health professionals to induce them to prescribe
3
4 Subsys, in violation of state law, including N.Y. Soc. Serv. Law s 366-d, 366-f.

5 455. As a result of the conduct set forth in this count, the State of New York
6
7 paid the improper Medicaid claims and has suffered actual damages.

8 456. Pursuant to §190(7) of the New York False Claims Act, the court may
9
10 award reasonable attorneys' fees, reasonable expenses, and costs, against Defendants,
11 and each of them..

12 457. **WHEREFORE**, Relator respectfully requests that judgment be entered
13
14 in favor of the State of New York and against Defendants, and each of them, as
15 follows:

16 458. A civil penalty of twelve thousand dollars, plus three times the amount
17
18 of damages which the state sustained because of the acts of Defendants; plus costs,
19 reasonable attorneys' fees, reasonable expenses, and any and all further relief that this
20 Honorable Court deems fit and proper.

21
22 **COUNT XXVI**
23 **VIOLATION OF THE NORTH CAROLINA FALSE CLAIMS ACT**
24 **(NORTH CAROLINA STATUTES – §§1-605 –18)**
25

26 459. The allegations of paragraphs 1 through 266 are realleged as though
27
28 fully set forth herein.

460. § 1-607 provides in pertinent part as follows:

(a) Any person who commits any of the following acts shall be liable to the State for three times the amount of damages that the State sustains because of the act of that person. A person who commits any of the following acts also shall be liable to the State for the costs of a civil action brought to recover any of those penalties or damages and shall be liable to the State for a civil penalty of not less than five thousand, five hundred dollars (\$5,500) and not more than eleven thousand dollars (\$11,000) for each violation:

(1) Knowingly presents or causes to be presented, a false or fraudulent claim for payment or approval;

(2) Knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim;

(3) knowingly conspires to commit a violation of clause (1), (2), (4), (5), (6), or (7) of this section;

• • •

(7) Knowingly makes, uses, or causes to be made or used, a false record or statement material to an obligation to pay or transmit money or property to the State or knowingly conceals or knowingly and improperly avoids or decreases an obligation to pay money or transmit property to the state
”
...

461. Defendants, and each of them knowingly presented, or caused to presented, false or fraudulent claims for payment or approval; knowingly made or used or caused the submission or use of false records or statements regarding Subsys material to these claims; and/or false records or statements in order to conceal, avoid, or decrease an obligation to pay or transmit money to the State of Minnesota.

1 Defendants, and each of them, conspired among themselves and with others to do
2 these things.

3
4 462. Additionally, Defendants, and each of them gave or caused to be given
5 'kickbacks' to physicians and other health care professionals to induce them to
6 prescribe Subsys, in violation of state law, including North Carolina Stat. 69J.23 et.
7 seq. Defendants, and each of them knowingly presented or caused to be presented
8 false claims for payment to the North Carolina Medicaid Program creating liability
9 for a false claims action pursuant to North Carolina's False Claims Act.
10

11
12 463. As a result of the conduct set forth in this count, the State of North
13 Carolina paid the improper Medicaid claims and has otherwise suffered actual
14 damages.
15

16 464. §§1-610 (d) and (e) also provide for an award against Defendants for
17 reasonable attorneys' fees, costs and expenses.
18

19
20 **COUNT XXVII**
21 **VIOLATION OF THE OKLAHOMA FALSE CLAIMS ACT**
22 **(OKLAHOMA STATUTES – TITLE 63, SECTION 5053)**

23 465. The allegations of paragraphs 1 through 266 are realleged as though
24 fully set forth herein.
25

26 466. Section 5053.1(B) provides in pertinent part as follows:
27
28

B. Any person who:

1. Knowingly presents, or causes to be presented, to an officer or employee of the State of Oklahoma, a false or fraudulent claim for payment or approval;

2. Knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the state;

3. Conspires to defraud the state by getting a false or fraudulent claim allowed or paid;

...

7. Knowingly makes, uses, or causes to be made or used, a false record to conceal, avoid, or decrease an obligation to pay or transmit money or property to the state, is liable to the State of Oklahoma for a civil penalty of not less than Five Thousand Dollars (\$5,000.00) and not more than Ten Thousand (\$10,000.00), unless a penalty is imposed for the act of that person in violation of this subsection under the Federal False Claims Act for the same or a prior action, plus three time the amount of damages which the state sustains because of the act of that person.

467. Defendants, and each of them knowingly presented or caused to be presented false claims for payment to the Oklahoma Medicaid Program creating liability for a false claims action pursuant to Oklahoma's False Claims Act.

468. Defendants, and each of them knowingly presented, or caused to presented, false records or statements regarding Subsys in order to get false or

1 fraudulent claims paid; and/or to conceal, avoid, or decrease an obligation to pay or
2 transmit money to the State of Oklahoma Medicaid Program.

3
4 469. As a result of the conduct set forth in this count, the State of Oklahoma
5 paid the improper Medicaid claims and has suffered actual damages.

6
7 470. Pursuant to Section 5053.4 of the Oklahoma False Claims Act, an award
8 of reasonable attorneys' fees, costs and expenses is also to be awarded against
9 Defendants.

10
11 471. **WHEREFORE**, Relator respectfully requests that judgment be entered
12 against Defendants, and each of them, and in favor of the State of Oklahoma as
13 follows:

14
15 472. A civil penalty of Ten Thousand (\$10,000.00), (unless a penalty is
16 imposed for the act of that Defendants in violation of this subsection under the
17 Federal False Claims Act for the same or a prior action), plus three time the amount
18 of damages which the State of Oklahoma sustained because of the act of that person;
19 plus costs, reasonable attorneys' fees, expenses, and any and all further relief that this
20 Honorable Court deems fit and proper.
21
22
23
24
25
26
27
28

COUNT XXVIII

VIOLATION OF THE STATE FALSE CLAIMS ACT
(RHODE ISLAND CODE - CHAPTER 9-1.1)

473. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein

474. Pursuant to Chapter 9-1.1, of the State False Claims Act of the State of Rhode Island:

(a) Any person who:

(1) Knowingly presents, or causes to be presented, to an officer or employee of the state or a member of the guard a false or fraudulent claim for payment or approval;

(2) Knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the state;

(3) Conspires to defraud the state by getting a false or fraudulent claim allowed or paid;

...

(7) Knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid or decrease an obligation to pay or transmit money or property to the state, is liable to the state for a civil penalty of not less than five thousand dollars (\$5,000) and not more than ten thousand dollars (\$10,000), plus three (3) times the amount of damages which the state sustains because of the act of that person. A person violating this subsection (a) shall also be liable to the state for the costs of a civil action brought to recover any such penalty or damages.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 475. Defendants, and each of them knowingly presented, or caused to
2 presented, false claims for payment; and/or false records or statements Subsys in
3 order get false claims paid; and/or to conceal, avoid, or decrease an obligation to pay
4 or transmit money to the State of Rhode Island Medicaid Program.
5

6 476. Additionally, Defendants, and each of them gave or caused to be given
7 'kickbacks' to physicians and other health professionals to induce them to prescribe
8 Subsys, in violation of state law, including 40-8.2-1, *et seq.*
9

10 477. Defendants, and each of them knowingly presented or caused to be
11 presented false claims for payment to the Rhode Island Medicaid Program creating
12 liability for a false claims action pursuant to Rhode Island's State False Claims Act.
13

14 478. As a result of the conduct set forth in this count, the State of Rhode
15 Island paid the improper Medicaid claims and has suffered actual damages.
16

17 479. Pursuant to Section 9-1.1-4 of the State False Claims Act, Defendants,
18 and each of them are also liable for attorneys' fees, costs and expenses.
19

20 480. **WHEREFORE**, Relator respectfully requests that judgment be entered
21 against Defendants, and each of them, and in favor of the State of Rhode Island as
22 follows:
23

24 481. A civil penalty of ten thousand dollars (\$10,000), plus three (3) times the
25 amount of damages which the state sustained because of the act of Defendants; plus
26 an award to the state for the costs of this civil; reasonable attorneys fees, costs and
27
28

1 expenses; and any and all other and further relief as this Honorable Court deems fit
2 and proper.

3
4 **COUNT XXIX**

5 **VIOLATION OF THE TENNESSEE MEDICAID FALSE CLAIMS ACT**
6 **(TENNESSEE 71-5-182 et seq.)**

7
8 482. The allegations of paragraphs 1 through 266 are realleged as though fully
9 set forth herein.

10
11 483. Section 71-5-182 of the Tennessee Medicaid False Claims Act provides
12 in pertinent part:

13 (a)(1) Any person who:

14
15 (A) Presents, or causes to be presented, to the state a claim
16 for payment under the Medicaid program knowing such
17 claim is false or fraudulent;

18 (B) Makes, uses, or causes to be made or used, a record or
19 statement to get a false or fraudulent claim under the
20 Medicaid program paid for or approved by the state
21 knowing such record or statement is false;

22 (C) Conspires to defraud the state by getting a claim
23 allowed or paid under the Medicaid program knowing such
24 claim is false or fraudulent; or

25 (D) Makes, uses, or causes to be made or used, a record or
26 statement to conceal, avoid, or decrease an obligation to
27 pay or transmit money or property to the state, relative to
28 the Medicaid program, knowing such record or statement is
false; is liable to the state for a civil penalty of not less than
five thousand dollars (\$5,000) and not more than ten
thousand dollars (\$10,000), plus three (3) times the amount

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 of damages which the state sustains because of the act of
2 that person.

3 484. Defendants, and each of them, knowingly presented or caused to be
4 presented false claims for payment to the Tennessee Medicaid Program creating
5 liability for a false claims action pursuant to Tennessee's Medicaid False Claims Act.
6

7 485. Defendants, and each of them, knowingly used or caused the use of false
8 or fraudulent records or statements in order to either get false claims paid.
9

10 486. As a result of the conduct set forth in this count, the State of Tennessee
11 paid the improper Medicaid claims and has suffered actual damages.

12 487. Pursuant to Section 71-5-183 of the Tennessee Medicaid False Claims
13 Act, Defendants, and each of them arev also liable for attorneys' fees, costs and
14 expenses.
15

16 488. **WHEREFORE**, Relator respectfully requests that judgment be entered
17 against Defendants, and each of them, and in favor of the State of Tennessee as
18 follows:
19

20 489. A civil penalty of ten thousand dollars (\$10,000), plus three (3) times the
21 amount of damages which the state sustains because of the act of that person; plus an
22 award of attorneys' fees, costs and expenses; and all further relief that this Honorable
23 Court deems fit and proper.
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XXX

VIOLATION OF THE TEXAS MEDICAID FRAUD PREVENTION ACT
(TEXAS HUMAN RESOURCE CODE 36.001 - 36.117)

490. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein.

491. Section 36.002 of the Texas Medicaid Fraud Prevention Act provides in pertinent part as follows:

A person commits an unlawful act if the person:

(1) knowingly makes or causes to be made a false statement or misrepresentation of a material fact to permit a person to receive a benefit or payment under the Medicaid program that is not authorized or that is greater than the benefit or payment that is authorized;

(2) knowingly conceals or fails to disclose information that permits a person to receive a benefit or payment under the Medicaid program that is not authorized or that is greater than the benefit or payment that is authorized;

(4) knowingly makes, causes to be made, induces, or seeks to induce the making of a false statement or misrepresentation of material fact concerning:

(A) the conditions or operation of a facility in order that the facility may qualify for certification or recertification required by the Medicaid program, including certification or recertification as: (i) a hospital; (ii) a nursing facility or skilled nursing facility; (iii) a hospice; (iv) an intermediate care facility for the mentally retarded; (v) an assisted living facility; or (vi) a home health agency; or

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 (B) information required to be provided by a federal
2 or state law, rule, regulation, or provider agreement
3 pertaining to the Medicaid program;

4 (5) except as authorized under the Medicaid program,
5 knowingly pays, charges, solicits, accepts, or receives, in
6 addition to an amount paid under the Medicaid program, a
7 gift, money, a donation, or other consideration as a
8 condition to the provision of a service or product or the
9 continued provision of a service or product if the cost of the
10 service or product is paid for, in whole or in part, under the
11 Medicaid program;

12 ****

13 (9) knowingly enters into an agreement, combination, or
14 conspiracy to defraud the state by obtaining or aiding
15 another person in obtaining an unauthorized payment or
16 benefit from the Medicaid program or a fiscal agent;

17 ****

18 (12) knowingly makes, uses, or causes the making or use of
19 a false record or statement to conceal, avoid, or decrease an
20 obligation to pay or transmit money or property to this state
21 under the Medicaid program.

22 492. Defendants, and each of them knowingly presented, or caused to
23 presented, false records or statements regarding Subsys in order to get false claims
24 paid and or in order conceal, avoid, or decrease an obligation to pay or transmit
25 money to the State of Texas Medicaid Program.

26 493. Additionally, Defendants, and each of them gave or caused to be given
27 'kickbacks' to physicians and other health care professionals to induce them to
28

1 prescribe Subsys, in violation of state law, including Tex. Hum. Res. Code §§ 32.039,
2 32.0391, and 36.002(a)(5).

3
4 494. Defendants, and each of them knowingly presented or caused to be
5 presented false claims for payment to the Texas Medicaid Program creating liability
6 for a false claims action pursuant to Texas's Medicaid Fraud Prevention Act.
7

8 495. As a result of the conduct set forth in this count, the State of Texas paid
9 the improper Medicaid claims and has suffered actual damages.

10
11 496. Section 36.052 of the Texas Medicaid Fraud Prevention Act provides in
12 pertinent part as follows:

13
14 (a) ..., a person who commits an unlawful act is liable to the
15 state for: (1) the amount of any payment or the value of
16 any monetary or in-kind benefit provided under the
17 Medicaid program, directly or indirectly, as a result of
18 the unlawful act, including any payment made to a third
19 party; (2) interest on the amount of the payment or the
20 value of the benefit described by Subdivision (1) at the
21 prejudgment interest rate in effect on the day the
22 payment or benefit was received or paid, for the period
23 from the date the benefit was received or paid to the date
24 that the state recovers the amount of the payment or
25 value of the benefit; (3) a civil penalty of . . . (B) not
26 less than \$1,000 or more than \$10,000 for each unlawful
27 act committed by the person that does not result in
28 injury to a person described by Paragraph (A); and (4)
two times the amount of the payment or the value of the
benefit described by Subdivision (1).

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 497. Pursuant to §36.110 and §36.117 of the Texas Medicaid Fraud
2 Prevention Act, Defendants, and each of them are also liable for attorneys' fees,
3 costs and expenses.
4

5 498. **WHEREFORE**, Relator respectfully requests that judgment be entered
6 against Defendants, and each of them, and in favor of the State of Texas as follows:
7

8 499. The amount of all payments or the value of the monetary or in-kind
9 benefit provided under the Medicaid program, directly or indirectly, as a result of the
10 unlawful acts of Defendants, and each of them, including any payments made to a
11 third parties; interest on the amount of said payment or the value of said benefit at the
12 prejudgment interest rate in effect on the day the payment or benefit was received or
13 paid, for the period from the date the benefit was received or paid to the date that the
14 state recovers the amount of the payment or value of the benefit; a civil penalty of . . .
15 \$10,000 for each unlawful act committed by the person that did not result in injury to
16 a person described by Paragraph 36.052(a)(3)(A); and two times the amount of the
17 payment or the value of the benefit described by Subdivision 36.052(a)(1); plus
18 attorneys' fees, costs and expenses, and any further relief that this Honorable Court
19 deems fit and proper.
20
21
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XXXI
VIOLATION OF VIRGINIA FRAUD AGAINST TAXPAYERS ACT
(VIRGINIA CODE 8.01-216.1 et seq.)

500. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein.

501. Section 8.01-216.3 of the Virginia Fraud Against Taxpayers Act provides in pertinent part as follows:

A. Any person who:

1. Knowingly presents, or causes to be presented, to an officer or employee of the Commonwealth a false or fraudulent claim for payment or approval;
 2. Knowingly makes, uses, or causes to be made or used, a false record or statement to get a false or fraudulent claim paid or approved by the Commonwealth;
 3. Conspires to defraud the Commonwealth by getting a false or fraudulent claim allowed or paid;
 - ...
 7. Knowingly makes, uses, or causes to be made or used, a false record or statement to conceal, avoid, or decrease an obligation to pay or transmit money or property to the Commonwealth;
- shall be liable to the Commonwealth for a civil penalty of not less than \$5,000 and not more than \$10,000, plus three times the amount of damages sustained by the Commonwealth.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 502. Defendants, and each of them obtained or attempted to obtain benefits or
2 payments pursuant to the Virginia Fraud Against Taxpayers Act and any amendments
3 thereto as provided for in Va. Code § 8.01-216.3 in a greater amount than that to
4 which it was entitled by means of willful false statements and misrepresentations
5 regarding Subsys, which caused a loss to the Commonwealth of Virginia.
6

7
8 503. Additionally, Defendants, and each of them gave or caused to be given
9 ‘kickbacks’ to physicians and other health professionals to induce them to prescribe
10 Subsys, in violation of state law, including Virginia Code § 32.1-315.
11

12 504. For each violation of the statute, the Commonwealth of Virginia is
13 entitled to recover treble damages from Defendants, and each of them. *See* Va. Code
14 § 8.01-216.3.
15

16 505. **WHEREFORE**, the Relator respectfully requests this Court to enter
17 judgment for the Commonwealth of Virginia and against Defendants, and each of
18 them, for an amount of three times the amount of damages sustained by the
19 Commonwealth of Virginia and a civil penalty of \$10,000 for each act of submitting
20 false statements by INSYS, Kapoor, Babich, and Burlakoff.
21
22
23
24
25
26
27
28

COUNT XXXII
VIOLATION OF THE WASHINGTON STATE
MEDICAID FRAUD FALSE CLAIMS ACT
RCE 74.66.005 et. Seq

506. The allegations of paragraphs 1 through 266 are realleged as though fully set forth herein.

507. A person is “liable to the government entity for a civil penalty of not less than five thousand five hundred dollars and not more than eleven thousand dollars, plus three times the amount of damages which the government entity sustains because of the act of that person if the person: (a) Knowingly presents or causes to be presented a false or fraudulent claim for payment or approval; (b) Knowingly makes, uses, or causes to be made or used, a false record or statement material to a false or fraudulent claim; c) conspires to commit one or more of the violations of this subsection (1); (d) has possession, custody, or control of property or money used, or to be used by the government entity and, knowingly delivers, or causes to be delivered, less than all of that money or property . . . (g) Knowingly makes, uses, or causes to be made or used, a false record or statement material to an obligation to pay or transmit money or property to the government entity.”

508. Pursuant Section 188(3) of the New York False Claims Act, proof of specific intent to defraud is not required.

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 509. Defendants, and each of them knowingly presented, or caused to
2 presented, false or fraudulent claims for payment or approval; false records or
3 statements to get a false or fraudulent claim paid; and/or to conceal, avoid, or
4 decrease an obligation to pay or transmit money to the Washington State Medicaid
5 Program.
6

7
8 510. Additionally, Defendants, and each of them gave or caused to be given
9 'kickbacks' to physicians and other health professionals to induce them to prescribe
10 Subsys, in violation of state law, including RCW 74.09.240.
11

12 511. Additionally, Defendants, and each of them had possession, custody, or
13 control over money which should have been delivered to the Washington State
14 Medicaid Program, and caused less than all of that money to be delivered.
15

16 512. As a result of the conduct set forth in this count, the State of Washington
17 paid the improper Medicaid claims and has suffered additional actual damages.
18

19 513. Pursuant to RCW 74.66.070(1)© of the Washington State Medicaid
20 Fraud False Claims Act, the court may award reasonable attorneys' fees, reasonable
21 expenses, and costs, against Defendants, and each of them..
22

23 514. **WHEREFORE**, Relator respectfully requests that judgment be entered
24 in favor of the State of Washington and against Defendants, and each of them, as
25 follows:
26
27
28

1 515. A civil penalty of eleven thousand dollars, plus three times the amount
2 of damages which the state sustained because of the acts of Defendants; plus costs,
3 reasonable attorneys' fees, reasonable expenses, and any and all further relief that this
4 Honorable Court deems fit and proper.
5

6
7 **COUNT XXXIII**
8 **ILLEGAL RETALIATION IN VIOLATION OF**
9 **FEDERAL FALSE CLAIMS ACT; 31 U.S.C. §3730(h),**
10 **AGAINST INSYS THERAPEUTICS, ONLY**

11 516. Guzman realleges and incorporates the allegations from Paragraphs 1
12 through 266, inclusive, as though fully set forth therein
13

14 517. Through reporting about and attempting to stop some of the fraudulent
15 conduct of Defendants, Relator was threatened, discriminated against, and ultimately
16 fired by INSYS Therapeutics because of lawful acts done by her in furtherance of
17 conduct protected by 31 U.S.C. §3729, et. seq.
18
19

20 518. Relator is entitled to all relief necessary to make her whole, including
21 reinstatement with the same seniority to the position she had before she was illegally
22 fired, 2 times the amount of back pay lost, interest on the back pay, and compensation
23 for any special damages sustained as a result of this illegal retaliation.
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

COUNT XXXIV
ILLEGAL RETALIATION IN VIOLATION OF
FLORIDA FALSE CLAIMS ACT; §68.088 FLORIDA STATUTES,
AGAINST INSYS THERAPEUTICS, ONLY

519. Guzman realleges and incorporates the allegations from Paragraphs 1 through 266, inclusive, as though fully set forth therein

520. Through reporting about and attempting to stop some of the fraudulent conduct of Defendants, Relator was threatened, discriminated against, and ultimately fired by INSYS Therapeutics because of lawful acts done by her in furtherance of conduct protected under this Act.

521. By its terms, §68.088 protects “[A]ny employee” who engages in protected conduct, thus broadening, for purposes of the Florida FCA, the more limited set of employees protected under the more general statute, the “Whistle-Blower Act”, §§ 112.3187 – 112.31895.

522. Moreover, because of the seal requirements peculiar to the Florida False Claims Act, Relator is, by definition, excused from strict compliance with the requirement that she report the fraud to the Florida Commission on Human Relations and follow the administrative process for required reporting while this Action remains under seal.

523. Relator is entitled to all relief necessary to make her whole, including reinstatement with the same seniority to the position she had before she was illegally

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1 fired, back pay lost, interest on the back pay, and compensation for any special
2 damages sustained as a result of this illegal retaliation.
3

4 **COUNT XXXV**

5 **ILLEGAL RETALIATION IN VIOLATION OF PUBLIC POLICY;**

6 **§§448.102 – 104, FLORIDA STATUTES,**

7 **AGAINST INSYS THERAPEUTICS, ONLY**

8
9 524. Guzman realleges and incorporates the allegations from Paragraphs 1
10 through 266, inclusive, as though fully set forth therein

11 525. Guzman objected to INSYS' illegal practices which were endangering
12 patients and resisted those practices. This was known to her supervisors to whom she
13 complained. She was fired in retaliation for this..
14

15 526. Relator is entitled to all relief necessary to make her whole, including
16 reinstatement with the same seniority to the position she had before she was illegally
17 fired, back pay lost, interest on the back pay, and compensation for any special
18 damages sustained as a result of this illegal retaliation.
19
20
21
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

PRAYER FOR RELIEF

WHEREFORE, the Relator Maria Guzman, acting on behalf of and in the name of the United States of America, and the various States and on her own behalf, prays that judgment be entered against Defendant, and each of them, for violation of the False Claims Acts as follows:

1. In favor of the United States against the Defendants and each of them for treble damages to the Federal Government from the submission of false claims, and the maximum civil penalties for each violation of the False Claims Act;
2. In favor of the Relator for the maximum amount pursuant to 31 U.S.C. § 3739(d) to include reasonable expenses, attorney fees, and costs incurred by the Relator;
3. In favor of each State identified hereinabove against the Defendants and each of them for treble damages to the Federal Government from the submission of false claims, and the maximum civil penalties for each violation of the False Claims Act;
4. In favor of Relator for the maximum amount allowed pursuant to each State False Claims Act;
5. For all costs of the False Claims Act civil action;

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

- 1 6. For the Relator on her retaliation causes of action under 31 U.S.C.
2 §3730(h), against Defendant INSYS Therapeutics, only, reinstatement with
3 the same seniority to the position she had before she was illegally fired, 2
4 times the amount of back pay lost, interest on the back pay, and
5 compensation for any special damages sustained as a result of this illegal
6 retaliation.
7
8
- 9 7. For the Relator on her causes of action under §68.088 Florida Statutes and
10 §§448.102 – 104, Florida statutes, against Defendant INSYS Therapeutics,
11 only, all relief necessary to make her whole, including reinstatement with
12 the same seniority to the position she had before she was illegally fired,
13 back pay lost, interest on the back pay, and compensation for any special
14 damages sustained as a result of this illegal retaliation; and
15
16
- 17 8. In favor of the Relator, the United States, and each State set forth
18
19 hereinabove for further relief as this court deems just and equitable.
20
21
22
23
24
25
26
27
28

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835


The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

Respectfully submitted,

Dated: June 13, 2016

THE EMPLOYMENT LAW GROUP
LAW OFFICE OF MARK KLEIMAN

By: 
David L. Scher, Esq.
California Bar No. 184562
R. Scott Oswald, Esq. (to be admitted *pro hac vice*)
The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
(202) 261-2802
(202) 261-2835 (facsimile)
dscher@employmentlawgroup.com
soswald@employmentlawgroup.com

By: 
Mark Kleiman, Esq.
Law Office of Mark Allen Kleiman
mkleiman@quitam.org
2907 Stanford Avenue
Venice, California 90292
310-306-8094

Attorneys for *Qui Tam* Plaintiff

DEMAND FOR A JURY TRIAL

Pursuant to Rule 38 of the Federal Rules of Civil Procedure and pursuant to the
local rules of this Court, the Relator demands a jury trial as to all issues so triable.

Respectfully submitted,

Dated: June 13, 2016

THE EMPLOYMENT LAW GROUP
LAW OFFICE OF MARK KLEIMAN

By:



David L. Scher, Esq.

California Bar No. 184562

R. Scott Oswald, Esq. (to be admitted *pro hac vice*)

The Employment Law Group, P.C.

888 17th Street, NW, Suite 900

Washington, D.C. 20006


(202) 261-2802

(202) 261-2835 (facsimile)

dscher@employmentlawgroup.com

soswald@employmentlawgroup.com

By:



Mark Kleiman, Esq.

Law Office of Mark Allen Kleiman

mkleiman@quitam.org

2907 Stanford Avenue

Venice, California 90292


310-306-8094

Attorneys for *Qui Tam* Plaintiff

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

CERTIFICATE OF SERVICE

I HEREBY CERTIFY that a true and correct copy of the foregoing **SECOND AMENDED COMPLAINT FOR VIOLATIONS OF THE FEDERAL FALSE CLAIMS ACT AND STATE FALSE CLAIMS ACTS** was served via USPS Certified Mail / Return Receipt Requested, on this 13th day of June, 2016, upon the addressees listed on the attached Service List.


Mark Kleiman

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

SERVICE LIST

Loretta E. Lynch, Esq. Attorney General of the United States Office of the Attorney General, Civil Division U.S. Department of Justice 950 Pennsylvania Avenue, NW Washington, DC 20530-0001	Andre Birotte, Esq. United States Attorney General United States Attorney's Office Central District of California 312 North Spring Street Suite 1200 Los Angeles, California 90012
Abraham Meltzer, Esq. Assistant United States Attorney Civil Fraud Section Federal Building, Suite 7516 300 N. Los Angeles St. Los Angeles, California 90012 Phone: 213-894-7155	Wendy Weiss, Esq. Chief, Civil Fraud Division United States Attorney's Office Central District of California 300 N. Los Angeles St., Room 7516 Los Angeles, CA 90012 Phone: 213-894-0444
John Lee Assistant United States Attorney United States Attorney's Office Central District of California 300 N. Los Angeles St. Los Angeles, California 90012 Phone: 213-894-3995	<u>CALIFORNIA</u> Martin Horan Acting Director, MFCU Medicaid Fraud Control Unit of California Office of the Attorney General 1425 River Park Drive, Ste. 300 Sacramento, CA 95815 Tel: 916-263-4675 / Fax: 916-263-0864 E-mail: martinjr.horan@doj.ca.gov Erika Hiramatsu Bureau of Medi-Cal Fraud Office of the Attorney General California Department of Justice 1455 Frazee Rd Suite 315 San Diego, CA 92108 (619) 688-7906 Erika.Hiramatsu@doj.ca.gov
<u>DELAWARE</u> Christina Showalter Director, MFCU Medicaid Fraud Control Unit of Delaware Office of the Attorney General 820 N French Street, 5th Floor Wilmington, DE 19801 Tel: 302-577-8859 / Fax: 302-577-3090 E-mail: Christina.showalter@state.de.us	<u>DISTRICT OF COLUMBIA</u> Brent Wolfingbarger Director, MFCU Medicaid Fraud Control Unit of D.C. Office of D.C. Inspector General 717 14th St., N.W., Suite 430 Washington, DC 20005 Tel: 202-727-2245 / Fax: 202-727-5937 E-mail: brent.wolfingbarger@dc.gov

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28

<u>FLORIDA</u> James D. Varnado Director, MFCU Medicaid Fraud Control Unit of Florida Office of the Attorney General PL – 01 The Capitol Tallahassee, Florida 32399 Tel: 850-414-3488 / Fax: 850-921-5194 E-mail: james.varnado@myfloridalegal.com	<u>GEORGIA</u> Van Pearlberg Director, MFCU Medicaid Fraud Control Unit of Georgia Office of the Attorney General 200 Piedmont Avenue S.E. West Tower, 19th Floor Atlanta, GA 30334 Tel: 404-656-5400 / Fax: 404-656-5444 E-mail: vpearlberg@law.ga.gov
<u>HAWAII</u> Christopher Young Director, MFCU Medicaid Fraud Control Unit of Hawaii Office of the Attorney General 333 Queen Street, 10th Floor Honolulu, HI 96813 Tel: 808-586-1169 / Fax: 808-586-1077 E-mail: christopher.d.young@hawaii.gov	<u>ILLINOIS</u> Brian Ley Director, MFCU Medicaid Fraud Control Bureau 801 South 7th St, 500A Springfield, IL 62703 Tel: 217-785-3321 / Fax: 217-524-6405 E-mail: brian_ley@isp.state.il.us
<u>INDIANA</u> Matthew Whitmire Director, MFCU Medicaid Fraud Control Unit of Indiana Office of the Attorney General 8005 Castleway Drive Indianapolis, IN 46250-1946 Tel: 317-915-5300 / Fax: 317-232-6523 E-mail: matthew.whitmire@atg.in.gov Lawrence J. Carcare II Deputy Attorney General Medicaid Fraud Control Unit Office of Indiana Attorney General Greg Zoeller 8005 Castleway Drive Indianapolis, IN 46250 P 317.915.5319 F 317.232.7979 Lawrence.Carcare@atg.in.gov	<u>LOUISIANA</u> Fred A. Duhy Jr. Director, MFCU Medicaid Fraud Control Unit of Louisiana Office of the Attorney General PO Box 94005 Baton Rouge, LA 70804-9005 Tel: 225-326-6210 / Fax: 225-326-6295 E-mail: duhyf@ag.state.la.us

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

MASSACHUSETTS

George Zachos
Director, MFCU
Medicaid Fraud Control Unit of
Massachusetts
Office of the Attorney General
One Ashburton Place
Boston, MA 02108
Tel: 617-963-2033 / Fax: 617-722-2008
E-mail: george.zachos@state.ma.us

MICHIGAN

David Tanay
Director, MFCU
Medicaid Fraud Control Unit of Michigan
Office of the Attorney General
2860 Eyde Parkway
East Lansing, MI 48823
Tel: 517-241-6509 / Fax: 517-241-6515
E-mail: tanayd@michigan.gov

MINNESOTA

Chuck Roehrdanz
Director, MFCU
Medicaid Fraud Control Unit of Minnesota
Office of the Attorney General
445 Minnesota St.
1200 Bremer Tower
Saint Paul, MN 55101-2219
Tel: 651-757-1299 / Fax: 651-282-5801
E-mail: chuck.roehrdanz@ag.state.mn.us

MONTANA

Debrah Fosket
Director, MFCU
Medicaid Fraud Control Unit of Montana
Division of Criminal Investigation
2225 11th Avenue
P.O. Box 201417
Helena, MT 59620-1417
Tel: 406-444-4606 / Fax: 406-444-7913
E-mail: dfosket@mt.gov

NEVADA

Mark N. Kemberling
Director, MFCU
Medicaid Fraud Control Unit of Nevada
Office of the Attorney General
555 East Washington Ave., Ste. 3900
Las Vegas, NV 89101
Tel: 702-486-3111 / Fax: 702-486-3871
E-mail: mkemberling@ag.nv.gov

NEW HAMPSHIRE

Karin M. Eckel
Director, MFCU
Medicaid Fraud Control Unit of New
Hampshire
Office of the Attorney General
33 Capitol Street
Concord, NH 03301-6397
Tel: 603-271-1256 / Fax: 603-223-6216
E-mail: Karin.eckel@doj.nh.gov

NEW JERSEY

Peter Sepulveda
Director
Medicaid Fraud Control Unit of New Jersey
Office of the Attorney General
One Appollo Drive
Whippany, NJ 07981
Tel: 609-984-7346 / Fax: 609-292-7410
E-mail: sepulvedap@njdcj.org

NEW MEXICO

Patricia Tucker
Director, MFCU
Medicaid Fraud Control Unit of New Mexico
Office of the Attorney General
111 Lomas NW, Suite 300
Albuquerque, NM 87102
Tel: 505-222-9082 / Fax: 505-222-9007
E-mail: ptucker@nmag.gov

The Employment Law Group, P.C.
888 17th Street, NW, Suite 900
Washington, D.C. 20006
Ph: 202.331.2883 • Fax: 202.261.2835

<u>NEW YORK</u> Amy Held Acting Director, MFCU Medicaid Fraud Control Unit of New York Office of the Attorney General 120 Broadway, 13th Floor New York, NY 10271 Tel: 212-417-5250 / Fax: 212-417-4284 E-mail: amy.held@ag.ny.gov	<u>NORTH CAROLINA</u> Charles Hobgood Director, MFCU Medicaid Fraud Control Unit of North Carolina Office of the Attorney General 5505 Creedmoor Rd., Suite 300 Raleigh, NC 27612 Tel: 919-881-2320 / Fax: 919-571-4837 E-mail: chobgood@ncdoj.gov
<u>OKLAHOMA</u> Ms. Mykel Fry Director, MFCU Medicaid Fraud Control Unit of Oklahoma Office of the Attorney General 313 N.E. 21st Street Oklahoma City, OK 73105 Tel: 405-522-2962 / Fax: 405-522-4875 E-mail: mykel.fry@oag.ok.gov	<u>RHODE ISLAND</u> James F. Dube Director, MFCU Medicaid Fraud Control Unit of Rhode Island Office of the Attorney General 150 S Main Street Providence, RI 02903 Tel: 401-274-4400 x 2410 / Fax: 401-222-3014 E-mail: jdube@riag.ri.gov
<u>TENNESSEE</u> Norman Tidwell Director, MFCU Medicaid Fraud Control Unit of Tennessee Bureau of Investigation 901 R.S. Gass Boulevard Nashville, TN 37216-2639 Tel: 615-744-4322 / Fax: 615-744-4659 E-mail: norman.tidwell@tn.gov	<u>TEXAS</u> Stormy Kelly Director, MFCU Medicaid Fraud Control Unit of Texas Office of the Attorney General 6330 Hwy 290 East, Suite 250 Austin, TX 78723 Tel: 512-371-4767 / Fax: 512-320-0974 E-mail: stormy.kelly@texasattorneygeneral.gov
<u>VIRGINIA</u> Randall L. Clouse Director, MFCU Medicaid Fraud Control Unit of Virginia Office of the Attorney General 900 E Main Street, 5th Floor Richmond, VA 23219 Tel: 804-692-0171 / Fax: 804-786-3509 E-mail: rclouse@oag.state.va.us	<u>WASHINGTON</u> Douglas D. Walsh Director, MFCU Medicaid Fraud Control Unit of Washington Office of the Attorney General P.O. Box 40114 Olympia, WA 98504-0114 Tel: 360-586-8872 / Fax: 360-586-8877 E-mail: dougw@atg.wa.gov